MicroRNA-125b modulates cell growth and metabolism and HBV replication by Deng, Wanyu
 
 
 
MicroRNA-125b modulates cell growth and 
metabolism and HBV replication 
 
 
 
 
Inaugural-Dissertation 
zur 
Erlangung des Doktorgrades 
Dr. rer. nat. 
der Fakultät für 
Biologie 
an der 
Universität Duisburg-Essen 
 
 
 
 
 
 
 
 
 
 
Vorgelegt von 
Wanyu Deng 
Aus Nanchang, P.R.China 
December 2013 
 
 
 
 
 Die der vorliegenden Arbeit zugrunde liegenden Experimente wurden am 
Institut für Virologie der Universität Duisburg-Essen oder durchgeführt. 
1. Gutachter: Prof. Dr. Mengji Lu 
2. Gutachter: Prof. Dr. Ralf Küppers 
3. Gutachter: 
Vorsitzender des Prüfungsausschusses: Prof. Dr.Peter Bayer 
Tag der mündlichen Prüfung: 07.03.2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Table of contents 
1 Introduction .................................................................................................................... 1 
1.1 Hepatitis B virus .................................................................................................... 1 
1.1.1 Molecular structure ...................................................................................... 1 
1.1.2 Life cycle ..................................................................................................... 2 
1.1.3 Host factors participate in HBV life cycle ................................................... 4 
1.1.4 HBV and hepatocellular carcinoma ............................................................. 6 
1.2 MicroRNA ............................................................................................................. 7 
1.2.1 MicroRNA biogenesis .................................................................................. 7 
1.2.2 MiRNA multiple functions .......................................................................... 9 
1.2.3 MiRNA and HCC ...................................................................................... 10 
1.2.4 MiRNA and cell cycle ................................................................................ 12 
1.2.5 MiRNA and metabolism ............................................................................ 14 
1.2.6 MiRNA and viral replication ..................................................................... 16 
2 Aims of the study .......................................................................................................... 19 
3 Materials and Methods ................................................................................................ 21 
3.1 Materials .............................................................................................................. 21 
3.1.1 Cells ........................................................................................................... 21 
3.1.2 Chemicals and reagents.............................................................................. 21 
3.1.3 Materials and instruments .......................................................................... 23 
3.1.4 Buffers ........................................................................................................ 25 
3.1.5 Commercial kits ......................................................................................... 26 
3.1.6 Plasmids ..................................................................................................... 26 
3.1.7 Antibodies .................................................................................................. 28 
3.1.8 MiRNA mimics and siRNA sequences...................................................... 29 
3.1.9 Prime sequences ......................................................................................... 30 
3.2 Methods................................................................................................................ 31 
3.2.1 Plasmid extraction ...................................................................................... 31 
3.2.2 Cell culture and transfection ...................................................................... 32 
3.2.3 Dual-luciferase reporter assay .................................................................... 32 
3.2.4 HBV progeny DNA detection .................................................................... 33 
3.2.5 HBV core particle extraction and detection ............................................... 34 
3.2.6 Hybridization probe preparation ................................................................ 35 
3.2.7 HBV RI extraction and hybridization ........................................................ 35 
3.2.8 Total protein collection .............................................................................. 37 
3.2.9 Cytoplasmic and nucleus protein purification ........................................... 37 
3.2.10 Western blot ............................................................................................. 37 
3.2.11 RNA extraction ........................................................................................ 38 
3.2.12 Real-time RT-PCR ................................................................................... 38 
3.2.13 Northern blot ............................................................................................ 39 
3.2.14 MiRNA quantification ............................................................................. 40 
3.2.17 RNA sequence assay ................................................................................ 42 
3.2.18 Statistical analysis .................................................................................... 42 
4 Results ........................................................................................................................... 43 
4.1 MiRNAs modulate HBV replication ................................................................... 43 
4.1.1 Liver tumor suppressor miRNAs enhance HBV replication specifically in 
different hepatoma cell lines ............................................................................... 43 
4.1.2 The effect of miR-125b on HBV replication is seed sequence specific, but 
is not binding to HBV genome directly .............................................................. 46 
4.1.3 MiR-125b enhances HBV RI and progeny production in dose dependence 
and its inhibitor could down-regulate HBV RI production ................................ 48 
4.1.4 MiR-125b regulates HBV in the post transcription steps and enhances 
HBV replication with miR-1 synergistically ...................................................... 51 
4.2 Tumor suppressor miRNAs are down-regulated in hepatoma cells..................... 57 
4.2.1 MiR-125b generation is weakened in hepatoma cells but is not regulated by 
HBx protein ......................................................................................................... 57 
4.2.2 Oncoprotein EZH2 has no influence on mature miR-125b generation while 
suppression of EZH2 protein could enhance HBV replication in Huh7 cell line 59 
4.3 MiR-125b modulates hepatoma cells growth and metabolism ............................ 63 
4.3.1 Tumor suppressor miRNAs do not regulate liver specific factors ............. 63 
4.3.2 MiR-125b arrests cell cycle at G1 phase and inhibits hepatoma cell 
proliferation......................................................................................................... 64 
4.3.3 MiR-125b regulates metabolism associated genes in hepatoma cells ....... 69 
4.3.4 MiR-125b regulates LIN28B/let-7 axis to modulate HBV replication ...... 70 
5 Disscussion .................................................................................................................... 77 
5.1 Cancer related miRNAs down-regulated in hepatoma cells could enhance HBV 
replication .................................................................................................................. 78 
5.2 MiRNAs which could arrest hepatoma cell at G1 phase are beneficial for HBV 
replication .................................................................................................................. 79 
5.3 MiRNAs involved in multiple steps in HBV life cycle directly or indirectly ..... 80 
5.4 MiR-125b is involved in regulating multiple pathways in hepatoma cells which 
may affect HBV replication ....................................................................................... 82 
6 Summary ....................................................................................................................... 85 
7 Zusammenfassung........................................................................................................ 86 
8 References ..................................................................................................................... 88 
9 Abbreviations ............................................................................................................. 108 
10 List of figures ............................................................................................................. 111 
11 List of tables ...............................................................................................................113 
12 Acknowledgements ...................................................................................................114 
13 Curriculum vitae .......................................................................................................115 
14 Erklärung...................................................................................................................116 
1 
 
 
1 Introduction 
1.1 Hepatitis B virus 
1.1.1 Molecular structure 
Hepatitis B virus (HBV) is a member of the hepadnavirus family and is one of the 
smallest enveloped animal viruses with a virion diameter of 42 nm (named Dane particle). 
The viral particle consists of an outer lipid envelope and an icosahedral nucleocapsid core 
composed of protein. The nucleocapsid encloses the viral DNA and a DNA polymerase 
that has reverse transcriptase activity similar to retroviruses (LOCARNINI 2004). The outer 
envelope contains embedded proteins which are involved in viral binding of, and entry 
into, susceptible cells. Besides the Dane particle, there are other two kinds of 
pleomorphic forms existing in patient serum, including filamentous and spherical bodies 
lacking a core (Figure 1.1). These two particles are not infectious and are composed of 
the lipid and protein that forms part of the surface of the virion, which is called the 
surface antigen (HBsAg), and is produced in excess during the life cycle of the virus 
(HOWARD 1986). 
 
Figure 1.1 Schematic models of HBV three particle forms 
From left to right: Dane particle, filamentous particle and spherical particle (HUNT 2011) 
The HBV genome (3.2 kb) consists of a partially double stranded, relaxed circular DNA 
(rcDNA) and is extremely compactly organized with widely overlapping open reading 
frame encoding the four structural and two nonstructural viral proteins. In addition, 
regulatory elements like promoters, enhancers and the polyadenylation and encapsidation 
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signals overlap with coding sequences (QUASDORFF and PROTZER 2010) (Figure 1.2). 
HBV four known proteins encoded by the genome called C, X, P, and S. The core protein 
is coded by gene C (HBcAg), and its start codon is preceded by an upstream in-frame 
AUG start codon from which the pre-core protein is produced. HBeAg is produced by 
proteolytic processing of the pre-core protein. The DNA polymerase is encoded by gene P. 
Gene S is the gene that codes for the surface antigen (HBsAg). The HBsAg gene is one 
long open reading frame but contains three in frame of "start" (ATG) codons that divide 
the gene into three sections, pre-S1, pre-S2, and S. Because of the multiple start codons, 
polypeptides of three different sizes called large, middle, and small (pre-S1 + pre-S2 + S, 
pre-S2 + S, or S) are produced (BECK and NASSAL 2007).The function of the protein 
coded by gene X is not fully understood (BOUCHARD and SCHNEIDER 2004). 
 
Figure 1.2 Genome organization of HBV 
The HBV genome is a 3.2 kb, partially double stranded, relaxed circular DNA represented by the 
bold inner circles. The thin, outer lines represent the different classes of transcripts (3.5, 2.4, 2.1 
and 0.7 kb) with arrowheads marking the start sites. Open arrows in the centre represent the four 
open reading frames encoding for the viral proteins (C, core protein; preC/C, hepatitis B e antigen; 
envelope proteins L, M and S; P, polymerase; X, X protein). Enhancer (Enh) I and II, direct 
repeat (DR) 1 and 2, the common polyadenylation site (An) and the encapsidation signal are 
indicated (QUASDORFF and PROTZER 2010). 
1.1.2 Life cycle 
HBV is one of a few known non-retroviral viruses which use reverse transcription as a 
part of its replication process so that its life cycle is complex (Figure 1.3). The early steps 
of how HBV virion infects hepatocytes are still unclear, but it is thought that first of all, 
HBV may be reversible and non-cell-type specific attachment to cell associated heparan 
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sulfate proteoglycans, then specific and probably irreversible binding to an unknown 
hepatocyte-specific preS1-receptor. This step presumably requires activation of the virus 
resulting in exposure of the myristoylated N-terminus of the L-protein (GLEBE et al. 
2005). 
There are two different entry pathways that have been proposed for viral entry: one is 
endocytosis followed by release of nucleocapsids from endocytic vesicles; the other is 
fusion of the viral envelope at the plasma membrane. The viral nucleocapsid in cytoplasm 
could then be transported along microtubules into nuclear and release rcDNA into the 
nucleoplasm (URBAN et al. 2010). 
In the nucleus, rcDNA could be repaired and form circular covalently closed DNA 
(cccDNA) by viral polymerase, combined with host cellular enzymes (NASSAL 2008). 
The cccDNA serves as a transcriptional template in the nucleus and utilizes the cellular 
transcriptional machinery to produce all viral RNAs. The RNA transcripts are then 
transported to the cytoplasm and translate into associated proteins, while pgRNA is 
assembled with core protein and polymerase proteins to form the RNA-containing 
nucleocapsid in cytoplasm. Maturation of RNA-containing nucleocapsid, including 
synthesis of the (-) DNA strand, pgRNA degradation and synthesis of the (+) DNA strand 
by the different enzyme activities of viral polymerase (LUCIFORA 2011). 
Newly formed DNA-containing nucleocapsid can be re-imported into the nucleus to form 
additional cccDNA molecule, this pathway is important for virus persistence in 
hepatocytes and also contributes to the relapse of viremia after stopping antiviral 
treatment in chronic HBV infected patients. On the other hand, nucleocapsids can also be 
directly bud into the endoplasmic reticulum (ER) or proximal Golgi membranes to 
acquire their glycoprotein envelope to trigger new virions secretion, or they are redirected 
towards to nucleus to amplify the cccDNA pool (GUIDOTTI and CHISARI 2006). 
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Figure 1.3 Schematic diagram of HBV life cycle 
Attachment: The virus gains entry into the cell by binding to a receptor on the surface of the cell 
and enters it by endocytosis. Penetration: The virus membrane then fuses with the host cell 
membrane releasing the DNA and core proteins into the cytoplasm. Uncoating: Because the virus 
multiplies via RNA made by a host enzyme, the viral genomic DNA has to be transferred to the 
cell nucleus by host proteins called chaperones. The core proteins dissociate from the partially 
double stranded viral DNA which is then made fully double stranded and transformed into 
covalently closed circular DNA (cccDNA) that serves as a template for transcription of four viral 
mRNAs. Replication: The largest mRNA, named pgRNA, which is longer than the viral genome, 
is used to make the new copies of the genome and to make the capsid core protein and the viral 
DNA polymerase. Assembly: Four viral transcripts undergo additional processing and go on to 
form progeny virions which are released from the cell or returned to the nucleus and re-cycled to 
produce even more copies. Release: The long mRNA is then transported back to the cytoplasm 
where the virion P protein synthesizes DNA via its reverse transcriptase activity (BECK and 
NASSAL 2007; BRUSS 2007). 
1.1.3 Host factors participate in HBV life cycle 
Virus replication relies on host cells. HBV gene expression can be modulated both in 
transcriptional or posttranscriptional process and also depend on the nature of the 
antiviral stimulus applied. Host cellular factors participate in HBV life cycle in almost 
every step from cccDNA formation, transcription, core particle formation and progeny 
secretion. 
The HBV cccDNA plays a key role in the life cycle of the virus and permits the 
persistence of infection. Nuclear cccDNA accumulates in hepatocyte nuclei as a stable 
minichromosome organized by histone and non-histone viral and cellular proteins and 
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then utilizes the cellular transcriptional machinery to produce all viral RNAs necessary 
for protein production and viral replication (LEVRERO et al. 2009; POLLICINO et al. 2006). 
Even though host factors that control cccDNA formation and cccDNA pool size are yet 
poorly defined, there is still a correlation between viremia levels and the acetylation 
status of cccDNA-bound histones (POLLICINO et al. 2006), indicating that epigenetic 
mechanisms can regulate the transcriptional activity of the cccDNA. 
Viral gene expression is controlled mainly at the transcriptional level, via four promoters 
and two enhancers (BAR-YISHAY et al. 2011). The Enhancer I element is located 
upstream to the HBx open reading frame and is activated by ubiquitous transcription 
factors (TFs) such as CCAAT/enhancer-binding protein (C/EBP), cyclic-AMP (cAMP) 
response element-binding (CREB), Ap-1, cAbl and RFX1 as well as by hepatocyte 
nuclear factor (HNF) 3 (FoxA) and the liver-enriched nuclear receptor (NR) HNF4a 
(LOPEZ-CABRERA et al. 1991; QUASDORFF and PROTZER 2010). Enhancer II activation is 
liver-specific, owing to the large number of liver-enriched TFs and NRs recruited: C/EBP, 
forkhead Box O1 (FoxO1), HNF3/FoxA, HNF4a, oestrogen-related receptors, farnesoid 
X receptor (FXR) and peroxisome proliferator-activated receptors (PPARs) (LI et al. 
1995; RAMIERE et al. 2008; SHLOMAI and SHAUL 2009). 
The viral core protein is a critical regulatory factor of the HBV life cycle. It contains 183 
amino acids in length which divides into an N-terminal assembly domain, a linker and a 
rich in serines and arginines C-terminal domain (CTD), as for CTD domain it is highly 
flexible and strongly binds to the encapsidated nucleic acids (MENG et al. 2011). 
Dynamic phosphorylation and dephosphorylation of the hepadnavirus core protein 
C-terminal domain are required for multiple steps of the viral life cycle, such as 
intracellular transport of HBV cores, core protein maturation, viral RNA packaging and 
DNA synthesis and also virion secretion (BASAGOUDANAVAR et al. 2007; KANN et al. 
1999; LAN et al. 1999; LEWELLYN and LOEB 2011; MELEGARI et al. 2005; NASSAL 1992; 
PERLMAN et al. 2005; RABE et al. 2003). It is still unclear how the state of 
phosphorylation regulates core protein function in RNA packaging, DNA synthesis, 
nuclear import, and potentially additional steps in the viral life cycle. One possibility is 
that the core protein exerts its multiple roles by interacting dynamically with distinct viral 
or host factors at different stages of viral replication, in a CTD phosphorylation 
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state-dependent fashion (LUDGATE et al. 2011). 
Moreover, HBV replication requires the host cells to be in G1 phase and may be 
associated with CDK2 activation, which is a kinase, incorporates into HBV capsids and 
could phosphorylate the HBV core protein CTD (LUDGATE et al. 2012). As for the mature 
nucleocapsid, since there is much dsDNA which is negatively charge, t it need cations to 
neutralize and stabilize (MENG et al. 2011). Cellular microRNAs, such as miR-125a-5p 
could up-regulate iron level so that they may regulate HBV replication (PARK et al. 
2012). 
Besides the above host regulation factors, there are other cell pathways that could also 
control HBV infection, such as host innate immunity. Type I IFNs, which are a factor for 
the innate immune response and are produced by all types of nucleated cells in response 
to virus infection, via activation of PRRs. IFNs elicit an antiviral response by binding to 
their cognate receptors, which trigger a signaling cascade (the JAK–STAT signaling 
pathway) leading to expression of IFN-stimulated genes (ISGs), whose products exhibit 
antiviral effects (CHANG et al. 2012). The effect of type I interferon on HBV replication 
is determined by viral load. They suppressed HBV replication when viral load is high and 
enhanced HBV replication when viral load is low. The suppression of HBV replication by 
IFN-I apparently involves both in transcriptional and post-transcriptional regulations 
whereas the enhancement of HBV replication by IFN- I is mediated by transcription 
factors HBF3r and STAT3 (TIAN et al. 2011). In addition to type I IFNs, other 
proinflammatory cytokines and chemokines also play essential roles in controlling HBV 
infection. At present, activation of innate immune response acts as therapeutic 
approaches for chronic hepatitis B infection. 
1.1.4 HBV and hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the fifth most common cancer and currently ranks the 
third leading cause of cancer-related deaths worldwide (GIORDANO and COLUMBANO 
2013). The liver tumor, which arises from hepatocytes, is often associated with liver 
cirrhosis resulting from chronic liver diseases. Among the environmental risk factors, the 
prevalence of chronic hepatitis B and C virus infections is linked directly to the incidence 
of HCC. It is well known that the HBV DNA genome is able to integrate into the cellular 
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chromosomal DNA, causing host genome rearrangements and enhancing the instability 
of the host chromosome, leading to large inverted duplications, deletions and 
chromosomal translocations (TAN 2011). 
There is no evidence for persistence within the tumor cells of a low level HBV 
multiplication potential. HBV DNA replicative molecules and cccDNA are detectable by 
polymerase chain reaction (PCR). Moreover, the association between HCC and HBV 
recurrence after liver transplantation, and the detection of cccDNA in HCC cells points 
toward the possibility of HBV replication in tumor cells. The latter could act as potential 
reservoirs for HBV recurrence, especially in patients who present with a recurrence of 
HCC (FARIA et al. 2008). So far, chronic and persistent infection with hepatitis B virus is 
a major risk factor for the development of HCC. Worldwide an estimated 350 million 
individuals are chronically infected with HBV (PRANGE 2012). Approximately 25% of 
chronically HBV-infected individuals will develop HCC (GANEM and PRINCE 2004). 
Chronic carriers of HBV have up to a 30-fold increased risk of HCC (FRANCESCHI et al. 
2006). In areas of high HBV endemicity, persons with cirrhosis have an approximately 
16-fold higher risk of HCC than the inactive carriers, and a 3-fold higher risk for HCC 
than those with chronic hepatitis but without cirrhosis (FATTOVICH et al. 2004). Although 
the mechanisms of oncogenesis of HBV remain obscure, several factors have been identi-
fied to be associated with a high risk of developing HCC among chronic hepatitis B 
(CHB) patients. Such as HBx, which is not binding directly to DNA, but rather acts on 
cellular promoters by protein-protein interactions and by modulating cytoplasmic 
signaling pathways, appears to play a critical role in the development of HCC (KUO and 
CHAO 2010; NGUYEN et al. 2008; ZHANG et al. 2006; ZHU et al. 2010). HBV exerts its 
oncogenic potential through a multi-factorial process, which includes both indirect and 
direct mechanisms that likely act synergistically (HINO and KAJINO 1994). 
1.2 MicroRNA 
1.2.1 MicroRNA biogenesis 
MicroRNAs (miRNAs) are a class of endogenous conserved short single-stranded RNA. 
The family of miRNA constitutes about 1–3% of the human genome. Most miRNA genes 
are situated within the intergenic regions and have their own transcription units. About a 
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quarter are located within exons or introns of other coding genes where their transcription 
is controlled by the host genes. MiRNAs can be transcribed as monocistronic transcripts 
or in polycistronic clusters, the latter involve several miRNAs situated on a single 
transcript being controlled by the same promoter (LAW and WONG 2011). 
In the nucleus, miRNA genes are transcribed as primary miRNAs (pri-miRNAs) by RNA 
polymerase II (Pol II). Structurally, pri-miRNAs consist of a 5′-7-methyl guanylate (m7G) 
cap, a characteristic imperfect stem-loop secondary structure, and a 3′-poly (A) tail. 
Pri-miRNAs are cleaved to precursor miRNAs (pre-miRNAs) of about 50–150 
nucleotides by Drosha, an endoribonuclease III (RNAse III), and its cofactor 
RNA-binding protein Pasha (DGCR8). The pre-miRNAs are then exported to the 
cytoplasm by exportin 5. This is further excised to double-stranded duplices of 20–23 
nucleotides by Dicer, an RNAse III enzyme. The miRNA duplex later separates into 
single-stranded mature miRNA, and incorporates into the RNA-induced silencing 
complex (RISC), which is composed of Argonaute proteins. This complex binds to the 
3′-untranslated region (3′ -UTR) of its target transcript and negatively regulates protein 
translation by a mechanism that depends on the complementarity between the miRNA 
and target messenger RNA. Partial complementarity results in translational repression, 
while complete complementarity triggers mRNA degradation (Figure 1.4). 
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Figure 1.4 MiRNA biogenesis and functions in animal cells 
In the nucleus, miRNAs are transcribed as either monocistronic or polycistronic pri-miRNAs by 
Pol II. Pri-miRNAs cleaved by Drosha and Pasha to pre-miRNAs are exported to the cytoplasm 
by exportin 5. In the cytoplasm, pre-miRNAs are excised to double-stranded miRNA: miRNA* 
duplex of 20–23 nucleotides by Dicer. The miRNA duplex unwinds to single-stranded mature 
miRNA, and incorporates into RNA-induced silencing complex (RISC), which is composed of 
Argonaute proteins. The miRNA/RISC complex binds to the 3′ -untranslated region (3′-UTR) of 
target cellular gene and negatively regulates gene expression with a mechanism depending on the 
complementarity between miRNA and its target mRNA. Perfect complementarity triggers mRNA 
degradation, while partial complementarity results in translational repression (LAW and WONG 
2011) . 
Although it is conventionally thought that miRNAs target the 3’UTR to down-regulate 
gene expression, there is evidence that miRNAs can also regulate mRNA expression in 
alternative. Some miRNAs target the coding regions or the 5’UTR to regulate gene 
expression whereas others can positively activate mRNA translation (KLOOSTERMAN et 
al. 2004; SAXENA et al. 2003). 
1.2.2 MiRNA multiple functions 
Although functional validation is frequently lacking, target prediction databases based 
primarily on Watson–Crick base-pairing (for example, TargetScan, miRanda and Pictar) 
have suggested that a single miRNA may simultaneously target more than 100 mRNAs 
(ROTTIERS and NAAR 2012). Similarly, a single mRNA could be regulated by many 
miRNA. Human miRNAs are predicted to control the activity of 30–60% of all 
protein-coding genes. Thus, miRNAs are integrated into vast regulatory networks that 
impinge upon a broad spectrum of biological events, including cell proliferation or 
differentiation, cancer development, viral replication and also immune response (HAGEN 
and LAI 2008). Moreover, miRNAs are stable in plasma, and differential plasma miRNA 
profiles have been described for many diseases, including fatty liver (CHEUNG et al. 
2008), atherosclerosis (FICHTLSCHERER et al. 2011), and cancer (FRIEL et al. 2010; 
KOSAKA et al. 2010; RABINOWITS et al. 2009; TAYLOR and GERCEL-TAYLOR 2008). 
Circulating extracellular miRNAs have enormous potential as novel disease biomarkers. 
MiRNAs could, therefore, be considered like hormones as a possible form of intercellular 
communication. 
10 
 
1.2.3 MiRNA and HCC 
More than fifty percent of genes that encode miRNAs are located at fragile sites or in 
cancer-associated regions of the genome and almost every type of human cancer analyzed 
has been associated with altered activities of miRNAs (WANG et al. 2012d). Thus, the 
potential of miRNAs to be robust biomarkers for cancer diagnosis, prognosis, and 
pathogenesis has been predicted. 
Recently, there are more and more miRNAs reported as etopic expression in HCC 
compared with normal hepatic tissues, such as miR-34a, 99a, 101, 106, 124, 125b, 
140-5p, 145, 195, 199a, 214, 216a/217, 224, 372, 375, 519d, 520b, 637 (GU et al. 2013; 
HE et al. 2012b; HOU et al. 2011a; HOU et al. 2011c; LI et al. 2011a; LI et al. 2009a; 
LIANG et al. 2010; NOH et al. 2013; SHEN et al. 2013; SU et al. 2009; WANG and LEE 
2011; XIA et al. 2012; XIA et al. 2013; XU et al. 2009; YANG et al. 2013; ZHANG et al. 
2011a; ZHANG et al. 2012b; ZHENG et al. 2012), which suggested the important roles of 
miRNAs in HCC development. 
In HCC, miRNA dysregulation plays a key role in mediating the pathogenicity of several 
etiologic risk factors and, more importantly, they promote a number of cancer-inducing 
signaling pathways (LAW and WONG 2011). For example, DNA methylation occurs in the 
early stage of cancer development, including HCC. Genomic hypomethylation increases 
chromosome instability while localized hypermethylation decreases tumor suppressor 
gene expression, thus increasing the risk of HCC development (PARK et al. 2007). While 
miRNAs could modulate host methylase expression, such as miR-101, which could target 
DNA methyltransferase 3A (DNMT3A) to modulate hepatocarcinogenesis (WEI et al. 
2013). 
MiRNAs with tumor suppression functions are often less expressed in HCCs compared to 
paired normal tissues. Most of the HCC-related miRNAs discovered so far belong to this 
class. Two important members of let-7 family, let-7a and let-7g inhibit HCC cell 
proliferation via down-regulating STAT3 and c-myc as well as up-regulating p16INK4A 
(LAN et al. 2011). The level of let-7g is significantly lower in metastatic HCCs compared 
to non-metastatic HCCs. High expression of miR-15b in HCCs predicts a low risk of 
HCC recurrence and is associated with antitumor effect via targeting Bcl-w, an 
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anti-apoptotic Bcl-2 family member (CHUNG et al. 2010). MiR-22 expression is 
down-regulated in HCCs and the low miR-22 expression is predictive of poor survival of 
HCC patients. In addition, ectopic expression of miR-22 significantly inhibits HCC cell 
proliferation and tumorigenicity (ZHANG et al. 2010b). miR-29c is significantly 
down-regulated in HBV-related HCCs. Over-expression of miR-29c in HepG2.2.15 cells 
effectively suppresses tumor necrosis factor alpha (TNFα)-induced protein 3 (TNFAIP3) 
and HBV DNA replication, it also inhibits cell proliferation and induces apoptosis 
(CHIANG et al. 2010; WANG et al. 2011a). MiR-99a, which is down-regulated in HCCs 
compared to the normal tissues, can induce cell cycle arrest in HCC cells, once miR-99a 
combines to its targets insulin-like growth factor 1 receptor (IGF1R) and mammalian 
target of rapamycin (mTOR), the cell cycle related proteins such as cyclin D1 are 
subsequently suppressed (LI et al. 2011b). MiR-101, which is also down-regulated in 
many human cancers including HCCs, targets the enhancer of zeste homolog 2 (EZH2), 
the key component of polycomb repressive complex 2 (PRC2) involving in the control of 
many cellular processes such as cell proliferation and differentiation. It also induces 
apoptosis of hepatoma cells via targeting Mcl-1, an anti-apoptotic member of Bcl-2 
family (SU et al. 2009). Over-expression of miR-125b in HCC cells suppresses cell 
growth and phosphorylation of Akt, and high expression of miR-125b is correlated with 
optimal survival of HCC patients (LI et al. 2008). MiR-199a-3p is frequently 
down-regulated in HCCs and HCC cell lines. MiR-199a-3p can efficiently suppress HBV 
replication and suppress HCC growth via targeting tumor-promoting p21 
protein-activated kinase 4 (PAK4), mTOR, and c-Met, while down-regulation of 
miR-199a-3p in HCCs is associated with a shorter time to recurrence after HCC resection 
(FORNARI et al. 2010; HOU et al. 2011b; SHEN et al. 2010). MiR-519d is down-regulated 
in HCCs and could suppress HCC growth via targeting MKi67, a 359-kDa nuclear 
protein reflecting cell proliferation rate (HOU et al. 2011c). 
In contrast to the tumor suppressor-like miRNAs, oncogene-like miRNAs regulate 
targeted genes and/or pathways that facilitate HCC growth and invasiveness. These 
miRNAs are often undetectable or less expressed in normal livers, but their expression 
levels are significantly elevated in HCCs. MiR-17-5p is able to activate the p38 
mitogen-activated protein kinase (MAPK) pathway and significantly increase the 
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phosphorylation of heat shock protein 27 (HSP27), and eventually promote the migration 
and proliferation of HCC cells (YANG et al. 2010a). MiR-30d is frequently up-regulated 
in HCCs and its expression is highly associated with HCC intrahepatic metastasis (YAO et 
al. 2010). MiR-143 is dramatically increased in metastatic HBV–HCC from both 
p21-HBx transgenic mice and HCC patients. It is partially transcribed by NF-κB and 
favors HCC invasiveness and metastasis via repressing fibronectin type III domain 
containing 3B (FNDC3B) expression (ZHANG et al. 2009). MiR-221/222, one of the most 
up-regulated miRNAs in HCCs, target the CDK inhibitor p27 and enhance 
hepatocarcinogenesis via targeting DNA damage-inducible transcript 4 (DDIT4), a 
modulator of mTOR pathway (PINEAU et al. 2010). MiR-221 can simultaneously affect 
multiple pro-oncogenic pathways via targeting Bmf and modulating p27 and p57 
(FORNARI et al. 2008; GRAMANTIERI et al. 2009). Over-expression of miR-222 is 
common in HCCs and confers metastatic potentials in HCC cells, possibly via activating 
Akt signaling (WONG et al. 2010). MiR-423 behaves as an oncogene in HCCs by 
down-regulating p21 (LIN et al. 2011). MiR-602 expression is significantly higher in 
HBV-associated liver inflammation, liver cirrhosis and HCC than in normal livers. It 
plays a pro-carcinogenic role in HBV-related hepatocarcinogenesis by inhibiting the 
tumor suppressor gene RAS association domain family 1A (RASSF1A) (YANG et al. 
2010b). 
1.2.4 MiRNA and cell cycle 
The cell cycle is the sequence of coordinated events resulting in reproduction of an 
individual cell into two daughter cells. A cell cycle can be divided into four distinct 
phases: S phase (synthesis phase), M phase (mitosis phase), and two gap phases G1 and 
G2. Two types of mechanisms are responsible for cell-cycle control: a protein 
phosphorylation cascade fine-tuned by cyclin/cyclin-dependent kinase (CDK) complexes 
and three supervisory restriction points, namely G1/S, G2/M, and metaphase checkpoints 
(CHEN et al. 2010). Cell-cycle control is a complicated process that is involved in the 
differential expression of a set of genes. 
The mechanisms governing cell cycle control by miRNAs are increasingly well 
understood. Several miRNAs have been reported to play a role in the control of cell cycle, 
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in particular at the G1/S checkpoint (LAW and WONG 2011). MiR-26a targets G1/S 
cyclins (both cyclin D2 and E2) in murine liver cancer (KOTA et al. 2009). Whereas 
miR-195 targets multiple genes (including cyclin D1, CDK6, and E2F3) of the G1/S 
transition in primary HCC (XU et al. 2009). Both miR-26a and miR-195 have been found 
to be frequently down-regulated in HCC, where they have been shown to cooperate in 
overcoming the G1/S cell cycle blockade through repression of E2F transcription (KOTA 
et al. 2009; XU et al. 2009). In addition, miR-221 in HCC has also been reported to target 
CDKN1B/p27/Kip1 and CDKN1C/p57/Kip2, both of which are CDK inhibitors 
(FORNARI et al. 2008). Both miR-106b and miR-93 can also target E2F1 (LI et al. 2009b). 
MiR-223 could target stathmin1 (STMN1), which is a microtubule destabilizer that 
sequesters tubulin for depolymerization and affects microtubule assembly (WONG et al. 
2008a). As microtubules have an important role in the segregation of metaphase 
chromosomes during mitosis, it is probable that miR-223 has a function in regulating the 
G2/M transition (LAW and WONG 2011) (Figure 1.5). 
 
Figure 1.5 Regulation of cell cycle by miRNA 
Several miRNAs take part in the control of cell cycle in HCC. (a) MiR-223 has been shown to 
target stathmin1 (STMN1), which is a regulatory protein involved in destabilizing the 
microtubules and plays a role in maintaining the dynamic nature of mitotic spindles at the G2/M 
transition. (b) MiR-26a can target both cyclin D2 and E2 while miR-195 has been shown to 
negatively regulate multiple genes, including cyclin D1, CDK6, and E2F3. In addition, miR-221 
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has been reported to target CDK inhibitors, p27 and p57. Members of miR-106b-25 cluster, 
miR-106b and miR-93, can repress E2F1 expression, whereby preventing excessive E2F1 
accumulation that may paradoxically result in apoptosis (LAW and WONG 2011). 
1.2.5 MiRNA and metabolism 
Proper control of metabolic homeostasis is crucial to the maintenance of human 
physiology and health. Besides a number of key transcription factors, such as liver X 
receptors (LXRs), CCAAT-enhancer-binding protein (C/EBP) and forkhead box protein 
O1 (FOXO1), respond directly or indirectly to cholesterol, lipids, glucose and insulin to 
rapidly alter gene expression programmes governing metabolic homeostasis (HORTON et 
al. 2002; NAKAE et al. 2008; ZELCER and TONTONOZ 2006). MiRNAs have recently been 
found to represent another crucial regulatory layer overlaying and intersecting with 
transcriptional control mechanisms in guiding metabolic homeostasis (ROTTIERS and 
NAAR 2012). 
Several miRNAs have recently been implicated in controlling both insulin signalling and 
glucose metabolism at multiple levels (Figure 1.6) (GUAY et al. 2011). For example, the 
pancreatic miRNA, miR-375, was shown to be required for the maintenance of pancreatic 
α-cell and β-cell mass in mice (POY et al. 2009). MiR-124a is also involved in pancreatic 
islet development, potentially through regulation of the FOXA2 transcription factor, 
which is involved in β-cell differentiation, and RAB27A, a GTPase required for insulin 
secretion (BAROUKH et al. 2007; LOVIS et al. 2008). MiR-9 may regulate insulin 
secretion through its inhibition of the transcription factor one cut homeobox 2 (OC2; also 
known as ONECUT2) and through SIRT1 (PLAISANCE et al. 2006; RAMACHANDRAN et al. 
2011), whereas miR-29a and miR-29b, which are highly expressed in the pancreatic islets 
of diabetic mice, inhibit the expression of monocarboxylate transporter 1 (MCT1) and its 
function in insulin release (PULLEN et al. 2011). Besides the above miRNAs which have 
key roles in controlling insulin secretion, other miRNAs could act in target tissues to 
regulate responses to insulin and glucose homeostasis. For example, miR-223 was found 
to inhibit glucose uptake through targeting GLUT4 (LU et al. 2010). MiR-33a and 
miR-33b may also influence insulin signalling and glucose regulation by targeting IRS2, 
SIRT6 and AMPKα1 (DAVALOS et al. 2011; ROTTIERS et al. 2011). A number of 
miRNAs have also been implicated in metabolic disorders associated with aberrant 
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insulin response. For example, miR-103 and miR-107 were recently shown to be 
up-regulated in livers of leptin-deficient (ob/ob) and diet-induced obese (DIO) mice 
(TRAJKOVSKI et al. 2011). 
 
Figure 1.6 MiRNA regulation of insulin signalling and glucose homeostasis 
Normally, following feeding, insulin is produced in pancreatic β cells and after release will reach 
target tissues such as the muscle, liver and adipose to cause uptake of glucose, reduce the 
production of glucose and activate fat production and storage. MiRNAs that affect diverse parts 
of insulin signalling in the pancreas, liver, muscle and adipose tissue have been identified. In 
disease conditions, such as impaired insulin secretion or insulin resistance, several miRNAs are 
up-regulated (marked with an arrow) (ROTTIERS and NAAR 2012). 
Lipids are structural components of cell membranes (for example, cholesterol and 
phospholipid) and are important for energy storage (for example, triglycerides) but can 
also act as signalling molecules (for example, steroid hormones). Lipids such as 
cholesterol and fatty acids are taken up in the diet and are synthesized de novo, 
predominantly in the liver. Regulation of the biosynthesis of cholesterol, fatty acids and 
phospholipids is mediated by transcription factors such as SREBPs (ROTTIERS and NAAR 
2012). 
The role of miRNAs in the regulation of lipid metabolism is just beginning to be explored 
(ROTLLAN and FERNANDEZ-HERNANDO 2012). Several miRNAs have been described to 
regulate lipid metabolism, including miR-122 which is highly expressed in the liver, and 
16 
 
it is estimated to account for approximately seventy percent of all liver miRNA 
(KRUTZFELDT et al. 2005; LAGOS-QUINTANA et al. 2002). MiR-122 inhibition by 
antisense oligonucleotides (ASO) in mice resulted in increased hepatic fatty-acid 
oxidation and a reduced cholesterol synthesis. In addition, miR-122 inhibition reduced 
total plasma cholesterol by 25–35%, and this was reflected by changes in both the LDL 
and HDL fractions (ESAU et al. 2006) . Besides miR-122, miR-33, which located within 
the sterol regulatory element-binding protein genes (Serbp) and was co-transcribed with 
their host genes, regulated cholesterol and fatty acid metabolism (DAVALOS et al. 2011; 
NAJAFI-SHOUSHTARI et al. 2010; RAYNER et al. 2011). Other miRNAs such as miR-370, 
miR-758, miR-106b, miR-378/378∗, miR-143, miR-27, miR-29a, miR-302a, and 
miR-335 have also been shown to regulate lipid homeostasis (CHEN et al. 2011b; ESAU et 
al. 2004; GERIN et al. 2010; HOEKSTRA et al. 2012; ILIOPOULOS et al. 2010; KIM et al. 
2012; LIN et al. 2009; NAKANISHI et al. 2009; RAMIREZ et al. 2011). 
1.2.6 MiRNA and viral replication 
Viruses are a class of intracellular pathogens with well established roles in the 
development of many diseases. Many cellular mechanisms, such as innate immunity and 
cell signaling pathways may participate in controlling viral pathogenesis (LECELLIER et al. 
2005). Alterations in miRNA expression profiles have emerged as important indicator of 
changes in gene expression that either favor or restrict virus replication (SCARIA et al. 
2007; UMBACH et al. 2008). 
Although HBV is a DNA virus, its transcripts might be targeted and regulated by cellular 
miRNAs, and accumulating evidence suggests that miRNAs modulate directly or 
indirectly on HBV transcription and replication (GUO et al. 2011a; LIU et al. 2011; 
POTENZA et al. 2011; WANG et al. 2012b; ZHANG et al. 2011b) (Figure 1.7). Thilde 
Nordmann Winther indicates the existence of a relationship between abundance of 
circulating miRNAs and immunological stages in the natural course of disease. Certain 
miRNAs may contribute to the establishment and maintenance of chronic hepatitis B 
infection in children (WINTHER et al. 2013). 
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Figure 1.7 Summary of cellular miRNAs effect on HBV transcription 
(A) Angled arrows indicate the HBV RNA start site for the major viral transcripts (Pre/core, 
PreS1, PreS, and X), and viral enhancer I and II are schematically depicted as boxes. DR I and 
DR II are two short repeats essential for viral replication. ARE represents two androgen response 
elements which were identified to locate at enhancer I region. Host cellular transcription factors 
binding position on HBV genome and the miRNAs targeting cellular factors known for regulating 
HBV transcription are shown. The arrow indicated an activated but the bars indicated an inhibited 
effect of the miRNAs on HBV transcription. (B) Positions of binding sequences in HBV 
transcripts proposed to be targeted by miRNAs are shown. Italic gray color represents miRNAs 
which were predicted to probably bind HBV transcripts by four well established target-prediction 
software (LIU et al. 2011). 
Hepatitis C virus infection is a major risk factor for chronic hepatitis, liver cirrhosis and 
HCC worldwide (KUMAR 2011). MiR-122 was found to be required for the propagation 
of hepatitis C virus (HCV). MiR-122 binds two positions in the 5’ UTR of the HCV 
genome, and this binding is essential to viral accumulation and propagation infected 
hepatocytes (JOPLING et al. 2005; RANDALL et al. 2007). 
In contrast to activated CD4+ T cells and differentiated macrophages, resting CD4+ T 
cells and monocytes are non-permissive for HIV-1 replication. Recently, certain miRNAs 
which are highly expressed in resting cells have been implicated in the regulation of the 
resting or quiescent phenotype, inhibiting the expression of cellular proteins that are also 
viral co-factors and finally mediate restriction of HIV (CHIANG and RICE 2012; XIAO et 
al. 2007; ZHOU et al. 2007). 
Besides host cellular miRNAs involving in mediation viral replication, virus could also 
encode miRNAs to benefit its survival. Such as Herpesviruses which have two distinct 
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phases in their lifecycle: latency and lytic replication (GREENE et al. 2007). Herpesviral 
miRNAs appear to promote viral latency by inhibiting viral lytic replication either 
through direct targeting of key viral replication genes or through manipulation of host 
pathways that regulate viral lifecycle (LEI et al. 2010; UMBACH et al. 2008). 
On the other hand, virus infection can also lead to changes in miRNA expression. 
Winther et al. have investigated the plasma miRNA profile of children chronically 
infected with HBV, and found there was differential plasma miRNA profiles in HBeAg 
positive and HBeAg negative children with chronic hepatitis B (WINTHER et al. 2013). 
Moreover, HBx was found to significantly up-regulate the expression of seven miRNAs 
but down-regulate the expression of eleven cellular miRNA, respectively. An inverse 
correlation was noted between the expression of HBx and that of the highly-expressed 
members of the let-7 family including let-7a, let-7b and let-7c in HCC patients (WANG et 
al. 2010b). HBV might also have evolved strategies to prevent infected cells from 
undergoing apoptosis and escape the innate or adaptive immune responses in host cells 
through regulating the expression of miRNAs (SARNOW et al. 2006). The well-defined 
miR-17-92 cluster and miR-29 are down-regulated following HIV-1 infection of Jurkat 
cells or PBMCs (HOUZET et al. 2008; SUN et al. 2012; TRIBOULET et al. 2007). 
Herpesvirus saimiri expresses a non-coding RNA, HSUR1 (H. saimiri U-rich RNA 1), 
which down-regulates miR-27 expression, resulting in low levels of miR-27 in 
herpesvirus-transformed marmoset T cells (CAZALLA et al. 2010). MiR-27 is also 
down-regulated following murine cytomegalovirus (MCMV) infection of cell lines and in 
vivo by a viral transcript which acts as a miR-27b target and mediates its degradation by 
the addition of post-transcriptional modifications (BUCK et al. 2010; LIBRI et al. 2012; 
MARCINOWSKI et al. 2012). 
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2 Aims of the study 
HBV infection could induce liver tissue to develop into HCC, meanwhile, in HCC, HBV 
replicative ability is weaker compared with hepatocytes, which means host cells status 
has direct correlation with HBV replication. Recently, there are more and more groups 
focusing on the roles of miRNAs in tumor development. In HCC tissue, there are some 
miRNAs reported deregulated, which are defined as oncogenous miRNAs or anti-tumor 
miRNAs. All these mean that miRNAs have multiple functions in liver physiology and 
pathophysiology and also virus infection. But the exact functions or regulatory 
mechanisms for each miRNAs on HCC development and viral replication are far from 
being fully understood, so it is meaningful to study miRNAs which may participate in 
HBV life cycle or liver tumor progress and investigate their regulatory mechanisms. 
In our previous study, Dr. Xiaoyong Zhang selected several miRNAs which were 
functionally related to cell differentiation, viral infection, innate immune response, 
hypoxia stress and cancer. He described miR-1 and 449a could enhance HBV replication 
and meanwhile block hepatoma cells staying at G1 phase. Thus, in the current study, we 
selected six miRNAs, including miR-99a, 101, 125b-5p, 199a-3p, 519d and 637, which 
are reported to be relatively highly expressed in normal liver, but decreased in HCC 
tissue so that they are considered to be as a kind of tumor suppression miRNAs, to verify 
their functions on hepatoma cells growth and test their influence on HBV replication, and 
also what mechanisms they may take. To elucidate these questions, we have investigated 
the following steps: 
① Transfect or co-transfect these miRNA mimics with a HBV genome containing 
plasmid pSM2 into hepatoma cell lines to screen out miRNAs which regulate HBV 
replication. 
② Transfect these miRNA mimics into hepatoma cells and treat cells with cell cycle 
inhibitors to analyse their influence on cell growth. 
③ To further study which steps miRNAs may take in the HBV life cycle, we analyse 
HBV from transcription to core particle formation and also progeny secretion after 
transfection miRNA mimics into hepatoma cells. 
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④ Since different hepatoma cell lines have different background, we also analyse the 
different appearances and molecule mechanisms miRNAs take in different cell 
lines. 
⑤ In order to figure out the molecule mechanisms these miRNAs may take in 
modulation of HBV replication, we use several molecular detection methods and 
also RNA sequence assay to analyse the possible target genes or pathways. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Cells 
Human hepatoma cell lines HepG2, Huh7 and HepG2.2.15 which integrated with HBV 
dimers (GenBank accession number: number: U95551) were kept at the Institute of 
Virology, University Hospital Essen. Con-1 cells with a subgenomic HCV replicon were 
kindly provided by Prof. Dr. Ralf Bartenschlager from University of Heidelberg. Primary 
human hepatocytes were isolated from liver transplantation donors by perfusion. 
3.1.2 Chemicals and reagents  
Name Company 
3M Sodium Acetate pH 5.5 Ambion 
Yeast RNA Ambion 
EDTA solution pH 8.0 AppliChem 
20× Sodium dodecyl supphate (SDS) AppliChem 
Ethanol absolute p.A. AppliChem 
Tris buffer pH7.4 / 8.0 / 8.8 AppliChem 
Fetal Calf Serum (FCS) Biochrom AG 
Tween 20 Biochemica 
RNAstable Biomatrica 
30% Acrylamide Solution BIO-RAD 
William’s Medium E Biotech GmbH 
Nocodazole CalbioChem 
Red Loading Buffer Cell Signaling 
SmartLadder  MW-1700-10 Eurogentec 
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AmershamTM Rapid-hyb Buffer GE Healthcare 
Rediprime Ⅱ DNA labeling system GE Healthcare 
IllustraTM MicroSpinTM S-200 HR columns GE Healthcare 
Amersham ECL Western Blotting Reagent GE Healthcare 
Alpha-P32 (dCTP) Hartmann Analytic GmbH 
TRIzol® Reagent Invitrogen 
10× TBE Buffer Invitrogen 
20× SSC Buffer Invitrogen 
D-PBS Invitrogen 
Lipofectamine® 2000 Reagent Invitrogen 
EcoR I and Buffer New England BioLab 
RPMI 1640 medium PAA Laboratories 
DMEM High Glucose medium PAA Laboratories 
L-Glutamine PAA Laboratories 
Trypsin-EDTA PAA Laboratories 
MEM Non Essential Amino Acids PAA Laboratories 
HEPES Buffer Solution PAA Laboratories 
Penicillin/Stretomycin PAA Laboratories 
PeqGOLD Protein-Marker Ⅳ Peqlab 
5× Green GoTaq™ Reaction Buffer  Promega 
Proteinase K QIAGEN 
RNase A QIAGEN 
Cell proliferation Reagent WST-Ⅰ Roche 
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2-propanol Roche 
Roti-phenol Roche 
2-propanol Roche 
DNAase 1 Roche 
10×SDS-PAGE Roche 
Hydrochloric Acid Sigma 
Dimethyl sulfoxide (DMSO) Sigma 
Chloroform Sigma 
3.1.3 Materials and instruments 
Amersham HybondTM-N+ GE Healthcare, USA 
Blotting Paper Sheets MUNKTELL﹠TILTRAK GmbH 
BIO WIARD KOJAIR BIO-FLOW Technik 
Bio Imaging System Syngene, UK 
Bin DER BIOTron Labortechnik GmbH 
CAWOMAT 2000 IR CAWO photochemisches Werk GmbH 
Cell culture plates Greiner Bio-One, Germany 
Centrifuge Megafuge 1.0R Heraeus, Germany 
Centrifuge Avanti J-26Xpi Beckman Coulter, Germany 
Centrifuge 5415 R   Eppendorf, Germany 
Centrifuge: Ultracentrifuge Optima L-70K Beckman Coulter, Germany 
CO2 incubator Thermo, Deuschland 
Cyclone Storage Phosphor Screen Packard, USA 
Duomax 1030 Oehmen Laborechnik 
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FACS Calibur Flow Cytometer Becton Dickinson, Germany 
FilterMate Harvester PerkinElmer, USA 
Flat-bottom 96-well microplates Falcon BD, Germany 
Fridge/Freezer (-20℃) AEG, Germany 
Freezer (-80℃) Thermo Forma, Germany 
HYBIDIZATION OVEN/SHAKER Amersham Pharmacia 
Julabo U3 Oehmen Laborechnik 
Light Cycler Roche, Switzerland  
Light Cycler Capillaries Roche, Switzerland 
Model 785 Vacuum Blotter BIO-RAD, USA 
Mini PROTEAN Tetra Cell BIO-RAD, USA 
Mini Trans-Blot Cell BIO-RAD, USA 
Nitrocellulose GE Healthcare, USA 
Power pack P25 Biometra, Germany 
Pipette tips (10ul, 200ul, 1ml) StarLab, Germany 
Plastic sterile pipettes (5ml, 10ml, 25ml) Greiner Bio-One, Germany 
Shaker (Duomax 1030) Heidolph, Germany 
Single-, multichannel pipettes Eppendorf, Germany 
TopCount.NXTTM Packard, UK 
T 3000 Thermocycler Biometra, Germany 
Vacuum Regulator BIO-RAD, USA 
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3.1.4 Buffers 
Name Component 
10× PBS (1 l) 
80g NaCl 
14.4g Na2HPO4 
2.0g KCl 
2.4g KH2PO4 
12% Separation gel (10 ml) 
3.3ml deionized water 
4.0ml 30% acrylamide  
2.5ml 1.5M Tris pH 8.8 
100μl 10% SDS 
100μl 10% AP 
4μl TEMED 
5% Concentration gel (5ml) 
3.15ml deionized water 
720μl 30% acrylamide  
540μl 1.0M Tris pH6.8 
45μl 10% SDS 
25μl 10% AP 
5μl TEMED 
10× Transfer buffer (1 l) 
142.6g Glycin 
30g Tris-base 
Lysis buffer for core particle extraction 
10mM Tris pH7.5 
1mM EDTA  
50mM NaCl  
8% sucrose 
26 
 
0.25% Nonidet P-40 
Lysis buffer for HBV RI extraction 
50mM Tris pH 7.4 
1mM EDTA 
1 % Nonidet P-40 
Denaturation buffer 
1.5M NaCl  
0.5M NaOH 
Neutralization buffer 
2.0M NaCl 
1.0M Tris-base  
2.5% hydrochloric acid 
3.1.5 Commercial kits 
Name company 
Dual-Glo Luciferase Assay Kit Promega 
QuantiFast SYBR Green RT-PCR Kit QIAGEN 
RNeasy Mini kit QIAGEN 
QIAamp DNA Blood Mini Kit (250) QIAGEN 
Gel Extraction Kit (50) QIAGEN 
MiScript II RT Kit (50) QIAGEN 
MiScript SYBR Green PCR kit QIAGEN 
Qiagen plasmid kits (Mini-,Midi-,Maxi-) QIAGEN 
Nuclear and Cytoplasmic Extraction Kit  Thermo Scientific 
3.1.6 Plasmids 
3.1.6.1 pSM2 
pSM2 which contains a head-to-tail tandem dimer of the HBV genome (GenBank 
accession number: V01460) was provided by Dr. Hans Will (Heinrich-Pette-Institute, 
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Hamburg, Germany). The plasmid encodes HBV proteins under the control of HBV core 
promoter, and HBV genome could be digested from vector pUC19 by single restriction 
endonuclease EcoR I. 
3.1.6.2 pGL3-HBV promoter report plasmids 
The luciferase reporter plasmids containing HBV promoters were constructed by Dr. 
Xiaoyong Zhang (ZHANG et al. 2011b). The regions of HBV core promoter 
(nt1648-1853), HBV X promoter (nt1237-1375), SP1 promoter (nt2224-2784), SP2 
promoter (nt2814-3123) were amplified from pSM2 plasmid and inserted into 
pGL3-basic vector between MluI and BglII restriction sites (Promega, Madison, WI), 
(Figure 3.1), resulting in the luciferase reporter vectors pSP1, pSP2, pCP and pXP 
respectively. 
 
Figure 3.1 pGL3-basic vector circle map (adopted from Promega) 
3.1.6.3 pMIR-REPORT system 
Full length of HBV genome sequence was generated from pSM2 plasmid by restriction 
enzyme SpeI digestion and cloned into the 3’UTR of luciferase gene of pMIR-REPORT 
vector (Ambion, Invitrogen). Four partial fragments of the HBV sequence (nt2840-837, 
nt837-1840, and nt1830-2849) and HBV RNA 3’UTR sequence (nt1841-1964) were 
amplified from pSM2 plasmid, digested with restriction enzymes MluI and HindIII, and 
cloned into the 3’UTR of luciferase gene by Dr. Xiaoyong Zhang (ZHANG et al. 2011b)  
(Figure 3.2). 
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Figure 3.2 Luciferase reporter plasmids containing HBV fragments 
(adopted from Dr. Xiaoyong Zhang) (ZHANG et al. 2011b) 
3.1.6.4 Renilla luciferase report vector 
The Renilla luciferase report plasmid was purchased from Clontech. 
3.1.7 Antibodies  
Name Source Company 
Anti-HBcAg  Rabbit pAb Abcam 
Phospho-Rb (ser795) Rabbit pAb Cell Signaling 
EZH2 Rabbit mAb Cell Signaling 
Cleaved PARP (Asp214) 
Antibody (Human Specific) 
Rabbit pAb Cell Signaling 
Caspase-3 Antibody Rabbit pAb Cell Signaling 
Anti-Albumin Rabbit mAb Cell Signaling 
LIN28B Rabbit pAb Cell Signaling 
Anti-human FXR/NR1H4  Mouse mAb PPMX 
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Bcl-2 (12) Antibody Mouse mAb Santa Cruz Biotechnology 
Anti-β-actin Mouse mAb Sigma 
3.1.8 MiRNA mimics and siRNA sequences 
Name Sequence (5’-3’) 
Hsa-miR-1 UGGAAUGUAAAGAAGUAUGUAU 
hsa-miR-99a AACCCGUAGAUCCGAUCUUGUG 
Hsa-miR-101 UACAGUACUGUGAUAACUGAA 
Hsa-miR-122 UGGAGUGUGACAAUGGUGUUUG 
Hsa-miR-125b-5p UCCCUGAGACCCUAACUUGUGA 
Hsa-miR-125a-5p UCCCUGAGACCCUUUAACCUGUGA 
Hsa-miR-125b-2-3p UCACAAGUCAGGCUCUUGGGAC 
Hsa-miR-199a-3p ACAGUAGUCUGCACAUUGGUUA 
Hsa-miR-519d CAAAGUGCCUCCCUUUAGAGUG 
Hsa-miR-637 ACUGGGGGCUUUCGGGCUCUGCGU 
Hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU 
Hsa-miR-98-5p UGAGGUAGUAAGUUGUAUUGUU 
MiR-control UCACAACCUCCUAGAAAGAGUAA 
SiR-control (Cat NO. # D-001210-02) Not provided by Thermo Scientic 
SiEZH2 6# CAGGATGGTACTTTCATTGAA 
SiEZH2 7# AACCATGTTTACAACTATCAA 
SiLIN28B 1# CTGGGATAACATAACTCCAGA 
SiLIN28B 4# AACATGATAAGCGTTGCTCAA 
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3.1.9 Prime sequences 
Name Sequence (5’-3’) / Cat. NO.  
HBV progeny DNA 
Forward: 
GTTGCCCGTTTGTCCTCTAATTC 
Reverse: 
GGAGGGATACATAGAGGTTCCTT 
HBV xRNA 
Forward:  
CCGTCTGTGCCTTCTCATCT 
Reverse:  
TAATCTCCTCCCCCAACTCC 
HBV pgRNA 
Forward:  
CTGGGTGGGTGTTAATTTGG 
Reverse:  
TAGGATAGGGGCATTTGGTG 
HCV RNA 
Forward:  
TCCCTGGAGAAGAGCTACGA 
Reverse:    
AGCACTGTGTTGGCGTACAG 
Hs_NR0B2_1_SG QT00061460 from QIAGEN 
Hs_NR1H4_1_SG QT00030870 from QIAGEN 
Hs_NR1H3_1_SG QT00065156 from QIAGEN 
Hs_PPARA_1_SG QT00017451 from QIAGEN 
Hs_PPARG_1_SG QT00029841 from QIAGEN 
Hs_HNF4A_1_SG QT00019411 from QIAGEN 
Hs_HNF1A_1_SG QT00085428 from QIAGEN 
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Hs_POU2F1_1_SG QT00086856 from QIAGEN 
All miScript primer assays and miRNA inhibitors are purchased from QIAGEN. 
3.2 Methods 
3.2.1 Plasmid extraction 
The transformation of chemically competent E.coli strains (DH5α, Invitrogen) was 
performed according to manufacturer’s instructions. Briefly, 50μl aliquots of bacteria 
were thawed on ice, mixed gently with 2-3μl of ligation mixture and incubated on ice for 
30 min. To improve the DNA absorption by bacteria, a heat shock for 30s at 42℃ 
followed by a subsequent incubation on ice for 2 minutes. Afterwards 200μl of SOC 
medium (Invitrogen) was added to the cells and the mixture was incubated on a shaker 
for 2 hours at 37℃. Using a sterile spatula the complete mixture was spread over an 
LB-agar plate containing a selective antibiotic (100 μg/ml of ampicillin or 50 μg/ml 
kanamycin). The plates were incubated overnight at 37℃. One bacterial colony was 
picked up from the LB agar plate, using a sterile pipette tip and transferred into the flask 
with LB-medium containing selective antibiotic. The volume of 2ml of the culture was 
used for Mini, 50ml for Midi and 250ml for Maxi preparations. After overnight 
incubation on the shaker at 37℃ the plasmid DNA was extracted using Qiagen plasmids 
Kits according to the manufacturer protocol. And the DNA concentration was quantified 
by spectrophotometric OD 260nm measurement as follows: 
Concentration [μg/ml] = OD 260nm × dilution factor × 50 
The purified plasmid DNA was checked by restriction enzyme digestion.
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3.2.2 Cell culture and transfection 
HepG2 and Huh7 were grown in Dulbecco modified Eagle medium supplemented 
with 10% fetal bovine serum, 100U/ml penicillin, 100μg/ml streptomycin, and 
maintained at 37℃ in a humidified 5% CO2 atmosphere. HepG2.2.15 and Con-1 cells 
were cultured with 500 μg/ml of G418 (Sigma-Aldrich). Primary human hepatocytes 
were cultured in William E medium with 250μl Insulin, 2% DMSO, and 125μl 
hydrocortisone hemisuccinate. 
The transfection of nucleic acids by transfection reagents (lipofectamine 2000, 
Invitrogen) was performed according to manufacturer’s instructions. Briefly, diluted 
lipofectamine 2000 transfection reagent and nucleic acids into Opti-MEM I reduced 
serum medium, mix gently and incubate for 5 minutes at room temperature, add 
nucleic acids diluents into transfection reagent diluents, mix gently by fingers 20 
times and then incubate for 20 minutes at room temperature. Finally, add the mixtures 
into plates with hepatoma cells drop by drop. 4-6 hours after incubation, discard the 
mixture and add new medium into cells. 
The volume of transfection reagents and Opti-MEM used in different plates 
Reagents / well 6-well 12-well 24-well 48-well 
Lipofectamine 2000 5-6μl 2-3μl 1.5μl 0.3μl 
Opti-MEM for nucleic acids 250μl 100μl 50μl 50μl 
Opti-MEM for reagent 250μl 100μl 50μl 50μl 
Opti-MEM for plate 1ml 500μl 300μl 100μl 
3.2.3 Dual-luciferase reporter assay 
48 hours post transfection, collected cells for Dual-luciferase activity detection 
according to manufacturer’s instructions. Briefly, add a volume of Dual-Glo® 
Luciferase Reagent equal to the culture medium volume to each well and mix. Wait at 
least for 10 minutes, then measure the firefly luminescence. Add a volume of 
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Dual-Glo® Stop & Glo® Reagent equal to the original culture medium volume to each 
well and mix. Wait at least for 10 minutes, and then measure luminescence. Calculate 
the ratio of luminescence from the experimental reporter to luminescence from the 
control reporter. Normalize this ratio to the ratio of a control well. 
3.2.4 HBV progeny DNA detection 
Purification HBV DNA from culture medium according to manufacturer’s instructions 
(QIAamp DNA Blood Mini Kit, QIAGEN). Briefly, pipetting 20μl QIAGEN Protease 
(or Proteinase K) into the bottom of a 1.5ml microcentrifuge tube and add 200μl 
sample, then add 200μl Buffer AL to the sample. Mix by pulse-vortexing for 15s and 
incubate at 56℃ for 10min. Briefly centrifuge the 1.5ml microcentrifuge tube to 
remove drops from the inside of the lid and add 200μl of ethanol (96 – 100%) to the 
sample, mix again by pulse-vortexing for 15s. After mixing, briefly centrifuge the 
1.5ml microcentrifuge tube to remove drops from the inside of the lid. Carefully apply 
the mixture from step 6 to the QIAamp spin column (in a 2ml collection tube) without 
wetting the rim, close the cap, and centrifuge at 6000 x g (8000rpm) for 1min. Place 
the QIAamp spin column in a clean 2 ml collection tube (provided), and discard the 
tube containing the filtrate. Carefully open the QIAamp spin column and add 500μl 
Buffer AW1 without wetting the rim. Close the cap and centrifuge at 6000 x g (8000 
rpm) for 1min. Place the QIAamp spin column in a clean 2ml collection tube 
(provided), and discard the collection tube containing the filtrate. Carefully open the 
QIAamp spin column and add 500μl Buffer AW2 without wetting the rim. Close the 
cap and centrifuge at full speed (20,000 x g; 14,000rpm) for 3min. Continue directly 
with step 10, or to eliminate any chance of possible Buffer AW2 carryover, perform 
step 9a, and then continue with step 10. Place the QIAamp spin column in a new 2ml 
collection tube (not provided) and discard the collection tube with the filtrate. 
Centrifuge at full speed for 1 min. Place the QIAamp spin column in a clean 1.5ml 
microcentrifuge tube, and discard the collection tube containing the filtrate. Carefully 
open the QIAamp spin column and add 100μl Buffer AE or distilled water. Incubate at 
room temperature for 1 min, and then centrifuge at 6000 x g (8000 rpm) for 1min. Use 
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as template for real time PCR or put the samples at -20℃ for long-term storage. 
Reaction mixture for real-time PCR 
Component Volume (total: 20μl) 
2×UDG mix 10μl 
Hope-forward prime 0.4μl 
Hope-reverse prime 0.4μl 
MgCl2 0.8μl 
BSA 1.0μl 
Template 2.0μl 
Aqua 5.4μl 
3.2.5 HBV core particle extraction and detection 
Wash cells by ice-cold PBS for one time and collect cells with cell lysis buffer (200μl, 
150μl, 100 μl/well for 6, 12, 24-well plate), mix with tip. Incubate on ice for 10min 
and centrifuge at 13000rpm for 10 min at 4℃. Transfer the supernatant to new tube, 
add 6uM MgCl2 and 0.8 mg/μl DNase 1 and 1.5 mg/μl RNase, and incubate for 20min 
at 37℃. Centrifuge at 13000rpm for 10min at 4℃, transfer the supernatant to new 
tube. Add 5× green loading buffer (5μl buffer for 20μl sample) and mix. 1.6% agarose 
gel electrophoresis for 2.5 h (volt = 45 V) at 4℃. 
Capsid protein detection by non-denaturing western blot as follows: 
Nitrocellulose membrane is transferred by absorption in 20× SSC overnight at RT and 
then blocking the membrane with 5% milk for 1hour at RT. The following steps are as 
like normal western blot. 
Capsid DNA detection by southern blot as follows: 
Denature gel for 30min at RT by shaking gently. Neutralize gel for 30min at RT by 
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shaking gently. Transfer DNA from gel to Nylon membrane by absorption overnight 
at RT. Crosslink by UV and the following steps are the same with southern blot 
hybridization. 
3.2.6 Hybridization probe preparation 
Digest pSM2 which contain HBV dimer by restriction enzyme EcoRⅠ 
Component Volume (total: 100μl) 
EcoRⅠ 1μl (20000 units/ml) 
10× NEB 2 10μl 
pSM2 10μg 
Aqua up to 100μl 
After digested at 37℃ for 2 hours, add 25μl 5× green loading buffer and run 0.8% 
agarose gel at 130v for 2 hours to separate two bands (3.2kb for HBV fragment and 
2.7kb for vector). Agarose gel extraction to quantify the HBV fragment concentration 
and diluted into 5μg/ul, the HBV fragment were put in -80℃ for long-term storage or 
used directly for southern blot hybridization. 
3.2.7 HBV RI extraction and hybridization 
Hepatoma cells were transfected and cultured for 3-4 days in 6-well plates. And then 
wash cells with PBS, add 800μl iced lysis buffer and incubate on ice for 10min. 
Collect the cell lysate, vortex vigorous for 15s and incubate on ice for 10min. 
Centrifuge at 13200rpm for 2min at 4℃ and transfer the supernatant to a new 2ml 
tubes which contain 8μl 1M MgCl2 and 8μl 10 mg/ml DNase1, mix gently by up and 
down 3-4 times, briefly centrifuge and incubate for 30min at 37℃. Briefly centrifuge 
and add 40μl 0.5M EDTA pH8.0 to a final concentration of 25mM, 80μl 10% SDS, 
mix by vortex and briefly centrifuge. Add 20μl 20 mg/ml proteinase K and incubate 
for 2 hours at 55℃. Briefly centrifuge and add phenol/chloroform (450μl + 450μl), 
mix and centrifuge at 13000rpm for 8min at RT. Transfer the upper liquid to a new 
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2ml tube, add 0.7V isopropanol, 0.1V NaAc (3M, pH5.2) and 2μg yeast RNA, mix 
and incubate over night at -20℃. Centrifuge at 13200rpm for 15min at 4℃ to collect 
the pellet. Wash the pellet with 1ml 75% ethanol and centrifuge at 8000rpm 2-5min at 
RT. Discard the supernatant carefully and dry the pellet for 5-10min. The pellets could 
be stored in -80℃ for long-term storage or used directly as follows: 
Dissolve the pellet in 15μl 1× TE buffer and add 5μl 5× green loading buffer. Load 
samples into 1% agarose gel and electrophoresis for 1.5-2 hours at 50v. Denaturation 
gel for 30min at RT with gentle agitation and wash gel with aqua. Neutralize for 
30min at RT with gentle agitation, wash gel one time with aqua and soak gel in 20× 
SSC. Transfer the DNA from gel to the Nylon membranes at 13Hg for 2 hours. 
Crosslink DNA on membranes at 150 J/cm2. 
Hybridization 
Dilute 5μl HBV DNA fragment (5μg/μl) in 41μl 1× TE in 1.5ml tube, mix and 
denature for 5min at 95℃, snap cool the DNA by placing on ice for 5min after 
denaturation. Prehybridize the membranes in 10ml AmershamTM Rapid-Hyb buffer 
at 68℃ for 10-20min, make sure there is no bubble between membrane and tube. 
Briefly centrifuge the denatured DNA and add into the reaction tube, add 2μl a-32P 
dCTP into the reaction tube and mix by pipette up and down about 12 times, moving 
the pipette tip around in the solution. Incubate at 37℃ for 10min and stop the reaction 
by adding 5μl of 0.2M EDTA. Snap off the bottom closure of the microspin columns 
and centrifuge for 1min at 3000rpm. Place the column in 1.5ml tube which contains 
salmon sperm and slowly apply the reaction sample to the resin, centrifuge at 
3000rpm for 2min. Denature the labeled DNA by heating to 95-100℃ for 5min, then 
snap cool on ice for 5min and centrifuge the tube briefly. Add purified labeled DNA to 
the pre-hybridization solution by directly dropping into hybridization tube and 
hybridize at 68℃ overnight. Wash the membranes at RT with gentle rotation in 50ml 
wash buffer I for 30 min two times. Wash the membranes at 65℃ with gentle rotation 
in 50 ml wash buffer Ⅱ for 30min two times. Detect radioactivity. 
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3.2.8 Total protein collection 
Three days after transfection, we collected cells according to manufacturer’s 
instructions (Red Loading Buffer, Cell Signaling). Briefly, aspirate media from 
cultures and wash cells with 1× PBS one time. Lysis cells by adding moderate 1× 
loading buffer. Immediately scrape the cells off the plate and transfer the extract to a 
microcentrifuge tube and keep on ice. Heat the samples to 95-100ºC for 5min, cool on 
ice and microcentrifuge for 2-5min. Load samples onto SDS-PAGE gel or put in -80℃ 
for long-term storage. 
3.2.9 Cytoplasmic and nucleus protein purification 
The separation of nuclear extract and cytoplasmic fractions from cultured cells were 
preformed according to manufacturer’s instructions (Thermo Scientific). Perform all 
centrifugation steps at 4℃, keep all samples and extracts on ice. Briefly, harvest cells 
with trypsin-EDAT and then centrifuge at 500×g for 5min. Wash cells by suspending 
the pellet with PBS and centrifuge at 500×g for 2 min. Remove the supernatant and 
leave the cell pellet as dry as possible. Add 100μl ice-cold CER I to pellet and vortex 
the tube vigorously on the highest setting for 15s, incubate on ice for 10min. Add 
5.5μl ice-cold CER Ⅱ and vortex the tube for 5s on the highest setting, incubate for 
1min on ice. Vor texing 5s on the highest setting and centrifuge for 5min at maximum 
speed. Immediately transfer the supernatant (cytoplasmic extract) to a new pre-chilled 
tube and place on ice until use or storage. Suspend the insoluble (pellet nuclei) 
fraction in 50μl ice-cold NER, vortex on the highest setting for 15s, place the samples 
on ice and continue vortexing for 15s every 10min, for a total of 40min. Centrifuge 
the tube at maximum speed for 10min and immediately transfer the supernatant 
(nuclear extract) fraction to a new pre-chilled tube. Store at -80℃ until use. 
3.2.10 Western blot 
Load protein samples into 10%-15% separate SDS-PAGE gels, electrophoresis at 
130v for 2 hours. Transfer protein to NC membrane at 100v for 1 hour on ice. 
Incubate the membrane in 5% blocking buffer by shaking gently for 1 hour at RT. 
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Incubate the membrane in primary antibody overnight at 4℃. Wash membrane by 
PBST for 10min by gentle shaking for three times. Incubate membrane in 
HRP-conjugated secondary antibody for 1 hour at RT with gentle shaking. Wash 
membrane by PBST for 10min by gentle shaking for three times. Detect enzyme 
activity by ECL reagents. 
3.2.11 RNA extraction 
Hepatoma cells were transfected and cultured in 12-well plates for three days. And 
then collect cells with 500μl Trizol reagent into 1.5ml tubes and incubate the 
homogenized sample for 5min at RT to permit complete dissociation of the 
nucleoprotein complex. Add 100μl chloroform and shake tubes vigorously by hand 
for 15s, incubate at RT for 2-3min, and then centrifuge at 12,000×g at 4℃ for 15min. 
Transfer the aqueous phase to a new tube and precipitate the RNA from the aqueous 
phase by mixing with 0.25ml 100% isopropyl alcohol. Incubate at RT for 10min and 
then centrifuge at 12,000×g at 4℃ for 10min. Remove the supernatant from the tubes, 
wash the RNA pellet with 1ml 75％ ethanol, and then centrifuge the tubes at 7500×g 
at 4℃ for 5min. Discard the wash and air dry the RNA pellet for 5-10min, dissolve 
RNA in RNase-free water. 
3.2.12 Real-time RT-PCR 
PCR for the detection of RNA was performed according to manufacturer’s 
instructions (one-step SYBR Green RT-PCR, QIAGEN). Briefly, after purified 
(RNase-Free DNase Set and RNeasy Mini Kit, QIAGEN), the RNA samples are 
diluted into 100ng/ul, and then a reaction mix as follows: 
Component Volume (total: 20μl) 
2× SYBR Green RT-PCR Master Mix 10μl 
10× primers 2.0μl 
QuantiFast RT mix 0.2μl 
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Template RNA 1.0μl 
RNase-free water 6.8μl 
Mix the reaction thoroughly and dispense appropriate volumes into PCR vessels. 
Program real-time cycler according to the following program: 
Step Time Temperature 
Reverse transcription 10min 50℃ 
PCR initial activation step 5min 95℃ 
Two-step cycling   
Denaturation 10s 95℃ 
Annealing/extension 30s 60℃ 
Number of cycles 35-40  
3.2.13 Northern blot 
All procedures should be carried out carefully to avoid RNase contamination. 
Preparation: Wash gel electrophoresis chamber, tray and combs three times with 
clean reagent in VE-water, and then wash with DEPC-water for two times, 100% 
ethanol one time and finally dry in ventilate hood. Prepare agarose gel: Dissolve 
1.2g agarose in 10ml NorthernMax 10× Gly prep running buffer diluted in 95ml 
DEPC water. Prepare RNA samples: Add 1V Glyoxal load Dye into 10μg RNA 
(final volume is less than 25μl), incubate at 50℃ for 30min and then cool in ice for at 
least 5min. Electrophoresis: Run agarose gel in 1× Gly runnig buffer at 50v for 2.5-3 
hours at 4℃. Transfer : RNase-free DEPC-water wash gel for 5-15min, 10× SSC 
shake for 15min one or two times, and then transfer gel to positive-charged nylon 
membrane in 20× SSC at 13Hg for 2 hours. Hybridization: See previous methods as 
southern blot. 
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3.2.14 MiRNA quantification 
First of all, extract total RNA from cells by Trizol. Then, 1μg total RNA is 
reverse-transcribed into cDNA according to manufacturer’s instructions (miScript Ⅱ 
RT Kit, QIAGEN). Briefly, prepare the reverse-transcription master mix on ice as 
follows: 
Component Volume (total: 20μl) 
5× miScript HiSpec Buffer 4.0μl 
MiScript Reverse Transcriptase Mix 1.0μl 
Template RNA variable 
RNase-free water up to 20μl 
Incubate for 60min at 37℃ and then incubate for 5min at 95℃ to inactivate miScript 
Reverse Transcriptase Mix. The reverse transcribed products used for mature 
miRNAs quantification by miScript SYBR Green PCR kit (QIAGEN). 
Reaction mixture as follows: 
Component Volume (total: 20μl) 
2× SYBR Green RT-PCR Master Mix 10μl 
10× miScript Universal Primer 2.0μl 
10× miScript Primer Assay 2.0μl 
Template RNA 2.0μl 
RNase-free water 4.0μl 
Cycle parameters as followed: a single step 95℃ for 15min followed by 40 cycles at 
94℃ (15s), annealing at 55℃ (30s) and extension at 70℃ (30s). 
For positive control/standard curve: Dilute synthetic miRNA to get 1010 copies/μl. 
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Prepare 20μl reverse-transcription reaction just like above, using 5μl synthetic 
miRNA (1010 copies/μl) and 50ng carrier bacterial RNA (yeast mRNA, 10 μg/μl). 
Incubate for 60min at 37℃. Incubate for 5min at 95℃ to inactivate and place on ice. 
Add 480μl bacterial carrier RNA (1 ng/μl concentration) to the 20μl reaction. Mix 
gently by pipetting up and down and centrifuge briefly. Note: This dilution yields 108 
copies cDNA/μl (assuming an efficiency of 100 %). 
Using the diluted cDNA mix from step 5 and carrier RNA (1 ng/μl). 
3.2.15 Cell proliferation 
Seed hepatoma cells into the 6-well plates and transfect with the miRNA. 24 hours 
post transfection, the cell were separated into 96-well plates at 10000 cells. After 24 
hours, the cells were starved for additional 16 hours (12-16 hours) within 100μl 
serum-free 1640 medium. Serum-free medium was replaced with 100μl complete 
medium, and 30min later, 0.5 μl/well (diluted in 50μl complete medium) of 
H3-thymidine was added. 6-8 hours later, cells were washed one time with PBS and 
then 100μl trypsin was added to digest cells for about 10min at 37℃. Suspend cells 
from 96-well plate and transfer the cells from plate into paper with scintillation 
counter. Detect radioactivity. 
3.2.16 Cell cycle analysis 
Wash cell with PBS, add 400μl Trypsin-EDTA and incubate for 5-8min at 37℃. Add 
800μl complete medium to inactivate Trypsin and harvest cells in 2ml tube. 
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Centrifuge at 1200rpm for 5min at 4℃. Drop off the medium with pipette and 
resuspend cells with 1ml PBS. Centrifuge at 1200rpm for 5min at 4℃. Drop off PBS 
and resuspend cells with pipette with 300μl PBS to get single cell. Add 900μl 100% 
ethanol and mix by vortex gently. Fix cells for at least 1hour at 4℃. 
PI staining 
Centrifuge at 3000rpm for 10min at 4℃ to get cell pellet. Drop off supernatant, 
resuspend by 1ml PBS and centrifuge at 3000rpm for 10min at 4℃ to get cell pellet. 
Drop off supernatant and PI staining (PI solution: 500μl PBS + 200 μg/ml RNase A + 
50 μg/ml PI + 0.1% Triton X-100), mix and incubate for 30min at 4℃. Add 1ml 
FACS and mix, then centrifuge at 3000rpm for 10min at 4℃. Drop off supernatant 
and wash cells once more, centrifuge at 3000rpm for 10min. Resuspend cells with 
200-400μl FACS and transfer into FACS tube. Analyse by flow cytometry. 
3.2.17 RNA sequence assay 
The RNA quantification were detected and analyzed by BGI TECH SOLUTIONS 
(HONGKONG) CO., LIMITED SERVICE AGREEMENT. 
3.2.18 Statistical analysis 
Statistical analyses were performed using Graph Pad Prism software version 5.1. 
Analysis of variance with Student’s t test was used to determine significant 
differences in multiple comparisons. P values < 0.05 were considered statistically 
significant. Data are presented as standard error of the mean (SEM). Gray-value 
analysis was processed by ImageJ software. 
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4 Results 
4.1 MiRNAs modulate HBV replication 
4.1.1 Liver tumor suppressor miRNAs enhance HBV replication specifically in 
different hepatoma cell lines 
To identify miRNA candidates influencing HBV replication, six miRNA mimics 
(sequences information are in Materials and Methods), which are reported of being 
highly expressed in normal liver and usually down-regulated in hepatocellular 
carcinoma tissues, were selected and transfected into HepG2.215 cells at a 
concentration of 20nM. HBV replicative intermediate (HBV RI) were isolated at day 
4 after transfection and analyzed by southern blot, culture media were collected for 
HBsAg and HBeAg analysis by CMIA test. As compared to control miR-C, HBV 
replication was enhanced slightly after transfected with miR-99a and strongly after 
transfected with miR-125b (Figure 4.1A, line 4 and line 6). We used miR-1 as positive 
control since our previous results confirmed that miR-1 could enhance HBV 
replication (ZHANG et al. 2011b). As like HBV RI, HBsAg and HBeAg from culture 
media were also increased after transfection miR-99a and miR-125b (Figure 4.1B). 
The other four selected miRNAs, including miR-101, 199a-3p, 519d and 637 could 
down-regulate HBV RI formation slightly compared with miR-C (Figure 4.1A, line 5 
and 7-9), but they had no obvious effect on HBsAg and HBeAg secretion (Figure 
4.1B). 
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Figure 4.1 The ability of HBV replication in HepG2.215 cells 
(A) HepG2.215 cells were transfected with different miRNA mimics at 20 nM. Cells were 
harvested at day 4 and the levels of HBV RI from intracellular core particles were determined 
by southern blot assay. The signals were analyzed and miR-C was set to 100. (B) Four days 
after transfection, we collected media for HBsAg and HBeAg detection by CMIA test. 
To further evaluate these miRNAs effects on HBV replication, 20nM of miRNA 
mimics and a replication competent clone of HBV pSM2 were cotransfected into 
Huh7 and HepG2 cells. In Huh7, besides the positive control, miR-1 could enhance 
HBV replication remarkably, miR-125b also enhanced HBV replication remarkably, 
miR-101, miR-519d enhanced HBV replication slightly compared to miR-C or mock 
group (Figure 4.2A, upper panel, line 5, 6, 8). While different from HepG2.215, 
HBsAg and HBeAg in culture media from Huh7 were not increased for these 
miRNAs which could enhance HBV RI from intracellular core particle (Figure 4.2A, 
below panel, line 5, 6, 8). The other three miRNAs, including miR-99a, 199a-3p and 
637 had no obvious effect on HBV replication. In HepG2, besides miR-1, only 
miR-125b could enhance HBV replication, other five miRNAs did not up-regulate 
HBV replication. Moreover, HBV proteins in culture media from HepG2 also have no 
difference compared with miR-C group for all groups (Figure B). 
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Figure 4.2 Influence of miRNAs on HBV replication in hepatoma cells 
HBV RI, HBsAg and HBeAg from Huh7 cells (A) and HepG2 cells (B). We cotransfected an 
HBV genome expression plasmid and different miRNA mimics into hepatoma cells. Cells 
were harvested at day 3 and the levels of HBV RI were determined by southern blot (upper 
panel). HBsAg and HBeAg from culture media were tested by CMIA (below panel). The 
signals were analyzed and miR-C was set to 100. 
In order to test if these miRNAs could also affect other hepadnavirus replication, such 
as hepatitis C virus, we transfected them into Con I cells which contain HCV 
subgenomic replicon, and we used miR-122 as positive control since miR-122 
transfection results in an increase of HCV RNA copy number (JOPLING et al. 2005). 3 
days after transfection, we extracted RNA for real time RT-PCR. Compared to miR-C 
or mock, positive miR-122 could up-regulate HCV replication significantly, while 
other six selected miRNAs did not increase HCV RNA copy number (Figure 4.3).  
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Figure 4.3 Influence of miRNAs on HCV replication 
Con I cells harboring HCV subgenomic replicon were transfected with different miRNA 
mimics (left panel) or different concentrations of miR-125b mimic (right panel), a nonspecific 
control of miR-C was set at a concentration of 20nM and cultured for 3 days. Total RNA were 
extracted and HCV copies were determined by real time RT-PCR and normalized against 102 
β-actin transcripts. * P<0.05. 
4.1.2 The effect of miR-125b on HBV replication is seed sequence specific, but is 
not binding to HBV genome directly 
Since miRNA acts functions by its 5 terminal seed sequence, we want to know if 
miR-125a-5p, which has consistent seed sequence with miR-125b-5p (Table 1, bold 
black characters), could also affect HBV replication. 
Table 1 Sequence of hsa-miR-125b and hsa-miR-125a 
miRNA  Sequence (5’-3’)  
has-miR-125b-5p  UCCCUGAGACCCUAACUUGUGA  
hsa-miR-125a-5p  UCCCUGAGACCCUUUAACCUGUGA  
We transfected 20nM of miRNAs into HepG2.215 or cotransfected pSM2 and 
miRNAs into Huh7 cells, then isolated HBV RI for southern blot analysis. As 
compared to miR-C, miR-125a-5p could also enhance HBV replication obviously 
both in HepG2.215 and Huh7 cell lines even though not as remarkably as 
miR-125b-5p (Figure 4.4). 
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Figure 4.4 Influence of miR-125a and miR-125b on HBV replication 
After transfection or cotransfection of pSM2 with 20nM miR-125b or miR-125a into 
HepG2.215 (left panel) and Huh7 (right panel), the HBV RI were extracted and determined 
by southern blot. The signals were analyzed and miR-C was set to 100. 
Computational analysis showed that miR-125 seed sequence could target HBV 
genome at polymerase and surface genes region (Table 2) (POTENZA et al. 2011), this 
suggested miR-125b may regulate HBV genes expression by directly binding to HBV 
genome. 
Table 2 Computational analysis of HBV genome targets for hsa-miR-125a/b-5p 
 
The most common methods for miRNA target validation are based on reporter gene 
constructs transfected in hepatoma cells. The rationale for using this assay is that the 
binding of a given cellular miRNA to the target, transcribed together with the 
luciferase coding sequence, will repress reporter protein production thereby reducing 
luciferase activity compared to a control. The HBV full length genome or four 
genomic fragments containing firefly luciferase report plasmids were constructed (foe 
details, please see materials and methods) and cotransfected with miR-C or miR-125a, 
125b and renilla luciferase report vector into Huh7 cells. Luciferase activities were 
measured 48 hours after transfection and the ratio of firefly to renilla luciferase 
activity was calculated, the luciferase activities were normalized to pMIR-REPORT 
vector not containing any HBV sequences. The results showed that miR-125b did not 
repress HBV genome containing luciferase report plasmids activity, and miR-125a 
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only weakened report plasmids which contained HBV fragment 1 activity slightly, but 
the difference between miR-C and miR-125a group was not significant (Figure 4.5). 
 
Figure 4.5 Luciferase activities from HBV genome containing plasmids 
Renilla and firefly luciferase reporter plasmids which contain HBV fragments were 
cotransfected at a concentration of 50μg/ml into Huh7 with 20nM of miR-C, miR-125b, or 
miR-125a and assayed for luciferase activity at 48 hours. We calculated the ratio of firefly to 
renilla for each well and the luciferase activity was normalized to empty vector transfection. 
All detections were performed in triplicate. 
4.1.3 MiR-125b enhances HBV RI and progeny production in dose dependence 
and its inhibitor could down-regulate HBV RI production 
We then transfected different concentrations of miR-125b into HepG2.215 cells or 
cotransfected pSM2 and different concentrations of miR-125b into Huh7 cells, 4 days 
or 3 days post transfection, isolated HBV RI for southern blot analysis. Compared 
with miR-C, miR-125b could enhance HBV RI production in dose-dependent manner 
both in HepG2.215 and Huh7 cell lines (Figure 4.6). 
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Figure 4.6 MiR-125b enhances HBV RI generation in dose dependent manner 
HBV RI in HepG2.215 which were transfected with 0, 5, 10, 20 or 40nM miR-125b mimics 
for 4 days  (A) and Huh7 which were cotransfected with an HBV genome expression 
plasmid pSM2 and 0, 5, 10 or 20nM miR-125b mimics for 3 days (B). The levels of HBV RI 
from intracellular core particles were determined by southern blot. The signals obtained from 
miR-C transfected samples were set to 1. 
Besides HBV RI, we also tested HBV progeny secretion by real time PCR and CMIA 
assay. 4 days after transfection different concentrations of miR-125b into HepG2.215 
cells, purified HBV DNA from culture media. Compared to miR-C or mock, 
miR-125b could enhance HBV progeny production in dose dependent manner 
remarkably (Figure 4.7).  
 
Figure 4.7 MiR-125b promotes HBV progeny secretion 
Four days post transfection with 0, 5, 10, 20, 40nM of miR-125b or miR-C into HepG2.215, 
HBV DNA was purified for real time PCR analysis (below panel) and HBsAg from culture 
media for CMIA test (upper panel). 
As previous results showed that exogenous transfected miR-125b could enhance HBV 
replication, this suggested that the inhibition of endogenous mature miR-125b may 
suppress HBV replication. We synthesized the hsa-miR-125b inhibitor named 
anti-miR-125b and transfected it into hepatoma cells to test its inhibition efficiency 
and influence on HBV replication. The real time PCR results showed that 
anti-miR-125b could suppress mature miR-125b generation remarkably both in 
HepG2.215 and Huh7 cell lines (Figure 4.8). 
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Figure 4.8 MiRNA inhibitor suppresses mature miR-125b generation 
HepG2.215 (left) and Huh7 (right) were transfected with 20nM of miRNA inhibitors, and 3 
days after transfection, we extracted total cellular RNA for reverse-transcription into cDNA 
and then real time PCR for mature miR-125b quantification. The relative mRNA copies were 
determined by a standard curve using serial dilutions of synthetic miR-125b mimic and 
normalized by U6 snRNA. All reactions were performed in triplicate. 
Next we tested miRNA inhibitors effect on HBV RI formation. Inhibition of 
miR-125b in HepG2.215 did not only down-regulate HBV replication, but was 
slightly up-regulated (Figure 4.9A), the reason may be that in HepG2.215 cell line, 
mature miR-125b was already very low (Figure 4.8A), so exogenous anti-miR-125b 
may have non-specific effect on miRNAs generation. While in Huh7, after 
transfection of 20nM anti-miR-125b for 3 days, HBV RI was down-regulated, but 
there was no effect on HBV proteins secretion (Figure 4.9B). 3 days after 
cotransfection different concentrations of anti-miR-125b and pSM2 into Huh7, we 
isolated HBV RI from intracellular core particle for southern blot analysis. Compared 
to anti-miR-C or mock, even though transfected low concentration of anti-miR-125b, 
such as 5 and 10nM, seemed slightly up-regulated HBV RI. The trend for 
anti-miR-125b suppression HBV RI formation in dose dependent manner was obvious, 
so as to HBV proteins secretion (Figure 4.9C). 
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Figure 4.9 Influence of miRNA inhibitors on HBV RI formation 
HBV RI, HBsAg and HBeAg in HepG2.215 cells (A) and Huh7 cells (B and C). 4 or 3 days 
post transfection miRNA inhibitors into hepatoma cells, HBV RI was isolated for southern 
blot analysis (upper panel) and culture media was collected for CMIA test (below panel). The 
signals were analyzed and miR-C was set to 100. 
4.1.4 MiR-125b regulates HBV in the post transcription steps and enhances HBV 
replication with miR-1 synergistically 
As HBV expresses proteins under the control of four promoters, so we supposed that 
miR-125b may regulate HBV promoter activities. We inserted the HBV four promoter 
regions into a luciferase report plasmid pGL3-basic to get pSP1, pSP2, pCP and pXP 
(Figure 4.10A and information in Materials and Methods), then cotransfected them 
with renilla luciferase report plasmid and miR-C or miR-125b into hepatoma cells. 48 
hours after transfection, we collected cells for dual-luciferase activity detection. As 
compared to miR-C, miR-125b had no influence on HBV SP1 and SP2 promoter 
activities, for CP and XP promoters, the results showed there was a little suppression 
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on their activity, but the difference between control and CP, XP were not significant 
(Figure 4.10B). 
 
Figure 4.10 Influence of miR-125b on HBV promoter activities 
(A) HBV promoter regions and the schematic for luciferase report plasmids. (B) The effect of 
miR-125b on HBV promoter activities. Renilla and luciferase reporters containing HBV 
promoter regions pSP1, pSP2, pCP, and pXP were cotransfected at a concentration of 50ng/ml 
with 20nM of miR-125b or miR-C into HepG2.2.15 cells and assayed for luciferase activity at 
48 hours. We calculated the ratio of firefly to renilla for each well, and luciferase activity was 
normalized against pGL3-basic control transfection. The values obtained from miR-C 
transfected samples were set to 1. All detections were performed in triplicate. 
In order to further verify that miR-125b has no effect on the four HBV promoters, we 
tested the RNA level of several host cellular transcription factors since they may 
participate in the regulation of HBV promoter activities. After transfection 20nM 
miR-C or miR-125b into HepG2.215 for 3 days, we purified RNA for real time RT 
PCR. And the results confirmed that miR-125b did not regulate these factors 
expression (Figure 4.11). 
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Figure 4.11 Influence of miR-125b on host cellular transcription factors 
(A) Binding sites of hepatocyte enriched transcription factors within HBV promoter and 
enhancer regions (QUASDORFF and PROTZER 2010). (B) Several transcription factors RNA in 
HepG2.215 were selected and tested by real time RT PCR after transfection with miR-C or 
miR-125b for 3 days. 
Besides the above experiments, we also tested HBV RNA level after transfection 
different concentrations of miR-125b into HepG2.215 or cotransfection pSM2 with 
different concentrations of miR-125b into Huh7 by real time RT PCR and northern 
blot, and all these results confirmed that miR-125b did not regulate HBV RNA 
transcription (Figure 4.12). 
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Figure 4.12 Influence of miR-125b on HBV RNA level 
HBV RNA from HepG2.215 cells (A) and Huh7 cells (B). After transfection or cotransfection 
pSM2 with 0, 5, 10, 20 or 40nM miR-125b mimics into hepatoma cells, cellular RNA were 
extracted by Trizol. The HBV pgRNA (upper panel), xRNA (middle panel) levels were 
determined by real-time PCR, and HBV total RNA were also detected by northern blot , 28S 
and 18S RNA were used as loading control (below panel). 
Then we wanted to figure out in which steps of the HBV life cycle miR-125b may 
play a role. Since the previous results showed that miR-125b could facilitate HBV RI 
from intracellular core particle accumulation in dose dependence, we supposed that 
miR-125b may be involved in HBV core protein expression and HBV nucleocapsid 
formation. We transfected different concentrations of miR-125b into HepG2.215 or 
cotransfected pSM2 and different concentrations of miR-125b into Huh7 cells, 3 days 
post transfection, collected cell lysate for HBcAg detection by western blot, isolated 
and tested HBV nucleocapsid both by western blot and southern blot. MiR-125b 
could up-regulate HBV core protein expression in dose-dependence slightly both in 
these two kinds of hepatoma cell lines (Figure 4.13A and B, upper panel). And 
compared with HBcAg accumulation, HBV nucleocapsid formation was up-regulated 
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by miR-125b in dose dependence more obviously in hepatoma cells (Figure 4.13A 
and B, below panel). 
 
Figure 4.13 MiR-125b enhances HBcAg expression and nucleocapsid formation 
in dose dependence 
HBcAg and nucleocapsid from HepG2.215 cells (A) and Huh7 cells (B). Hepatoma cells were 
transfected with 0, 5, 10, 20, 40nM miR-125b or cotransfected different concentrations of 
miR-125b with pSM2 for three days. Cell lysates were harvested at day 3 for total HBcAg 
detection (upper panel), nucleocapsid was extracted and detected both by western blot and 
southern blot (below panel). The signals were analyzed using β-actin as loading control and 
miR-C was set to 100. 
Since Dr. Xiaoyong Zhang demonstrated that miR-1 enhanced HBV replication 
during transcription (ZHANG et al. 2011b), while miR-125b regulated downstream 
steps, we suggested that miR-1 and miR-125b may have a synergistic effect on the 
enhancement of HBV replication. We confirmed that miR-1 could up-regulate HBV 
core promoter activity while miR-125b did not up-regulate by dual luciferase activity 
assays (Figure 4.14A). By transfection and western blot, we confirmed that both 
miR-1 and miR-125b could up-regulate HBV core protein expression and capsid 
formation both in HepG2.215 and Huh7 cells. As for miR-125b, even though the 
enhancement on HBcAg was not as obvious as miR-1, its enhancement on capsid 
formation was more remarkable than miR-1 (Figure 4.14B and C). We also tested the 
difference for the effect on HBV RI between individually transfected 
miR-1/miR-125b and cotransfected miR-1 with miR-125b. Compared to transfection 
of miR-1 or miR-125b alone, cotransfection of miR-1 with miR-125b could 
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up-regulate HBV RI accumulation more effectively both in HepG2.215 and Huh7 cell 
lines (Figure 4.14C and D). 
 
Figure 4.14 MiR-1 and miR-125b have synergistic effect on upregulation of HBV 
replication 
(A) MiR-1 and miR-125b on HBV core promoter activity. The relative luciferase expression 
was determined and the values obtained from miR-C transfected samples were set to 1. * 
P<0.05. HBcAg and HBV capsid from HepG2.215 cells (B) and Huh7 cells (C). Three days 
after transfection or cotransfection of pSM2 and 20nM miR-C, miR-1 or miR-125b into 
hepatoma cells, the total cellular proteins and nucleocapsid was extracted for HBcAg 
detection. The signals were analyzed using β-actin as loading control and miR-C was set to 
100. HBV RI from HepG2.215 cells (D) and Huh7 cells (E). Four or three days after 
transfection or cotransfection of pSM2 with 5nM miR-1, miR-125b or 5nM miR-1 plus 5nM 
miR-125b into cells, the HBV RI were extracted and detected by southern blot. We used 
miR-C to complement each transfection sample to 10 nM, and the signals of miR-C sample 
were set to 100. 
As IFN-α could suppress HBV replication when viral load is high, and enhance HBV 
replication when viral load is low, the suppression of HBV replication by IFN-α 
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involves both transcriptional and post transcriptional regulations (TIAN et al. 2011). 
So we want to investigate if miR-125b has a synergistic or antagonistic effect on HBV 
replication with IFN-α. We transfected 20nM miR-C or miR-125b into HepG2.215 
cells, and changed transfection mixture into new cell culture media containing 10000 
UI/ml IFN-α 6 hours post transfection. Four days later, we isolated HBV RI from 
intracellular core particle for southern blot analysis. The results showed that even 
though miR-125b could enhance HBV replication significantly, IFN-α could weaken 
this effect, so as in Huh7 cell lines (Figure 4.15). This means that the suppression for 
the IFN-α, and the enhancement for the miR-125b on HBV replication do not interfere 
with each other. 
 
Figure 4.15 Influence of miRNA transfection and IFN treatment on HBV 
replication 
(A) HBV RI from HepG2.215 transfected with 20nM miR-C or miR-125b, and meanwhile 
add 10000 UI/ml IFN-α was added for 4 days culturing. (B) HBV RI from Huh7 
cotransfected with pSM2 and 20nM miR-C or miR-125b, and meanwhile 100 UI/ml IFN-α 
was added for 3 days culturing. 
4.2 Tumor suppressor miRNAs are down-regulated in hepatoma cells 
4.2.1 MiR-125b generation is weakened in hepatoma cells but is not regulated by 
HBx protein 
We then selected and synthetised miR-99a, miR-101 and miR-125b primers to detect 
these mature miRNAs quantity in primary human hepatocytes (PHH) and hepatoma 
cells since they had different influence in HBV replication in different hepatoma cell 
lines. By miScript PCR, we confirmed that the expression of all these three miRNAs 
were significantly down-regulated in hepatoma cells compared with in PHH. For 
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miR-99a and miR-125b, their expression in HepG2.215 were more than 105 fold 
lower compared with in PHH. In HepG2 and Huh7, even though their differences 
were not so remarkable, there were still more than 2 fold and 40 fold differences for 
both miR-99a and miR-125b. As to miR-101, the expressions in three hepatoma cell 
lines were more than 10 fold lower compared with in PHH, especially in Huh7 cells 
(Figure 4.16). 
 
Figure 4.16 Quantification of mature miRNAs in PHHs and hepatoma cells 
Total cellular RNA, including miRNA, was extracted from cells using Trizol. Total RNA (1μg) 
was reverse transcribed into cDNA (20μl) with miScript Reverse Transcription Kit Ⅱ from 
QIAGEN. The real time PCR for the quantification of miR-99a, 101, 125b was carried out 
with miScript Primer Assay and miScript SYBR Green PCR Kit from QIAGEN. Cycle 
parameters were as followed: a single step at 95℃ for 15min followed by 40 cycles at 94℃ 
(15s), annealing at 55℃ (30s) and extension at 60℃ (30s). An aliquot of cDNA (2μl) was 
used for each assay. The relative miRNA quantification was normalized by U6 snRNA. All 
reactions were performed in triplicate. MiRNA quantification in hepatoma cells was 
compared with in PHH. * P<0.05. 
Song et al. found that HBx protein could inhibit the transcription of miR-122 by 
binding transcription factors PPARγ as they compared miR-122 in HepG2 to 
HepG2.215, which derived from HepG2 and is characterized by having stable HBV 
expression (SONG et al. 2013). And in our above results, we also found that mature 
miR-125b was much lower in HepG2.215 compared within Huh7 and HepG2, so we 
supposed that miR-125b generation could also be regulated by HBx. We knocked 
down HBx in HepG2.215 and then detected the generation of mature miR-125b, we 
used siR-ctrl and siHBs as control. While the real time RT PCR results showed that 
even though the knocking down efficience for both siHBs and siHBx in HepG2.215 
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cells was more than half percentage, they had no influence on mature miR-125b 
generation (Figure 4.17). 
 
Figure 4.17 Knocking down HBs and HBx on mature miR-125b generation 
Three days after transfection of 20nM siRNAs into HepG2.215 cells, we purified total cellular 
RNA, including miRNA using Trizol reagents. HBs, HBx RNA level (upper two panels) 
which were normalized against 103 β-actin transcripts and mature miR-125b which were 
normalized by U6 snRNA (below panel) were tested. All reactions were performed in 
triplicate. 
4.2.2 Oncoprotein EZH2 has no influence on mature miR-125b generation while 
suppression of EZH2 protein could enhance HBV replication in Huh7 cell line 
As mature miR-125b were down-regulated significantly in hepatoma cells compared 
to PHH, so we want to find out which molecules may participate in this phenomenon. 
MiR-125b gene promoter was enriched in CpG dinucleotides which are benefit for 
DNA methylation, so miR-125b transcription is modulated by DNA methylase 
(ALPINI et al. 2011; HE et al. 2012a; ZHANG et al. 2011c). Enhancer of zeste homolog 
2 (EZH2) acts as a methyltransferase which is thought to be involved in targeting 
transcriptional regulators and is reported to epigenetically silence multiple tumor 
suppressor microRNAs in liver (AU et al. 2012; ONDER et al. 2012). So we supposed 
60 
 
that EZH2 may participate in the modulation of mature miR-125b generation in HCC. 
We synthesized two kinds of siRNAs against EZH2, including EZH2 6# and 7#, the 
knocking down efficiency for EZH2 6# in HepG2.215 was about 71%, EZH2 7# was 
about 79% (Figure 4.18A, upper panel). In Huh7 cells, the knocking down efficiency 
for EZH2 6# was about 51%, and EZH2 7# was about 71% (Figure 4.18B, upper 
panel). We tested mature miR-125b quantity 3 days post transfection of siEZH2 in 
hepatoma cells. Compared to siR-ctrl, knocking down of EZH2 had no obvious effect 
on mature miR-125b generation in hepatoma cells (Figure 4.18A and B, below 
panels). 
 
Figure 4.18 Influence of knocking down EZH2 on miR-125b generation 
Protein EZH2 expression and mature miR-125b generation in HepG2.215 cells (A) and Huh7 
cells (B). Three days after transfection with 20nM siR-C, siEZH2 6# or 7# into hepatoma 
cells, we collected total cellular proteins for EZH2 protein detection by western blot (upper 
panel) and extracted RNA for mature miR-125b quantification by miScript PCR (below 
panel). The signals were analyzed using β-actin as western blot loading control and miR-C 
was set to 100. 
As oncoprotein EZH2 is up-regulated in HCC compared with in normal liver tissue, 
there are several miRNAs reported targeting EZH2 to regulate liver cancer metastasis 
(XIA et al. 2012; ZHENG et al. 2012). So we supposed that the tumor suppressor 
miR-125b may also modulate EZH2 expression and finally regulate HBV replication. 
We transfected different concentrations of miR-125b into HepG2.215 and Huh7 cells, 
3 days post transfection, collected cell lysate to test EZH2 protein expression by 
western blot. Compared with miR-ctrl, miR-125b could down-regulate total EZH2 
protein in hepatoma cells in dose dependent manner (Figure 4.19A). Next, we tested 
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HBV RI after knocking down of EZH2 in hepatoma cells. We selected siEZH2 6# for 
transfection since the knocking down efficiency for 6# was higher than 7# in both 
hepatoma cell lines. In HepG2.215, 4 days post transfection 20 nM siEZH2 6#, HBV 
RI not only increased, but decreased slightly (Figure 4.19B, left panel). While in 
Huh7 cell line, 3 days post cotransfection pSM2 and siEZH2 6#, HBV RI was 
increased obviously (Figure 4.19B, right panel). We then cotransfected pSM2 and 
different concentrations of siEZH2 6# into Huh7 for 3 days, and analyzed HBV core 
protein, HBV RI and nucleocapsid by western blot and southern blot assays. The 
results confirmed that knocking down of EZH2 in Huh7 could up-regulate HBV core 
protein expression, HBV RI and nucleocapsid formation in a dose dependent manner 
(Figure 4.19C). 
 
Figure 4.19 MiR-125b affects EZH2 expression and HBV replication in Huh7 
(A) Three days after transfection with 0, 5, 10, 20 or 40nM miR-125b into HepG2.215 (upper 
panel) and Huh7 (below panel), collect total cellular proteins for EZH2 detection, using 
β-actin as loading control and miR-C was set to 100. (B) Four days after transfection 20 nM 
siRNAs into HepG2.215 (left panel) or three days post cotransfection 20 nM siRNAs and 
pSM2 into Huh7 (right panel), we isolated HBV RI for southern blot analysis. (C) Three days 
after cotransfection pSM2 and 0, 5, 10, 20nM siEZH2 into Huh7 cells, we collected HBcAg 
for western blot, isolated HBV RI and nucleocapsid for southern blot analysis. We used 
β-actin as loading control. 
As knocking down EZH2 did not up-regulate HBV replication in HepG2.215 cells, 
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we wanted to know the different roles in different hepatoma cell lines for nuclear 
protein EZH2, whose total protein expression was suppressed by miR-125b both in 
HepG2.215 and Huh7 cell lines. We transfected different concentrations of miR-125b 
into HepG2.215 and Huh7 cells, 3 days post transfection, collected cells for 
separation of nuclear and cytoplasmic proteins individually. Western blot analysis 
showed that miR-125b could suppress cytoplasmic EZH2 protein but have no effect 
on nuclear EZH2 protein in HepG2.215 cell line (Figure 4.20A). Where as in Huh7 
cells, miR-125b could suppress the EZH2 protein both in the cytoplasm and in the 
nucleus in dose dependent manner (Figure 4.20B).  
 
Figure 4.20 Distribution of EZH2 after miR-125b transfection 
Three days after transfection with 0, 5, 10, 20 or 40nM miR-125b into HepG2.215 (A) or 
Huh7 (B), we collected cytoplasmic and nuclear proteins for EZH2 detection. We used β-actin 
as loading control. 
In order to further verify EZH2-miR-125b roles in HepG2.215 cell line, we 
transfected siRNA or miRNA into cells for two times. We first transfected 20 nM 
miR-ctrl, miR-125b or siR-ctrl, siEZH2 6# into HepG2.215, and two days post 
transfection, split cells into new plates for an additional transfection. Three days after 
the second transfection, we separated cytoplasmic and nuclear proteins to test the 
EZH2 protein expression. And four days after second transfection, we isolated HBV 
RI from intracellular core particle for southern blot analysis. Compared to miR-ctrl, 
miR-125b enhanced HBV RI formation remarkably after two times transfection 
(Figure 4.21A, below panel). For the EZH2 protein, even though miR-125b could 
reduce its quantity in cytoplasm, there was still no effect in nuclear EZH2 protein 
accumulation (Figure 4.21A, upper and middle panels). On the other hand, after 
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transfection of siEZH2 into HepG2.215 for two times, EZH2 almost could not be 
detected in cytoplasm, and EZH2 in nucleus was also decreased to 28 percent 
compared with siR-ctrl (Figure 4.21B, upper and middle panels). While even though 
most EZH2 has already been knocked down after two times transfection with siEZH2, 
HBV RI was still not increased in HepG2.215 cell line (Figure 4.21B, below panel). 
This means that in HepG2.215 cell line, EZH2 is not a regulative protein for the 
modulation of HBV replication. 
 
Figure 4.21 HBV replication and EZH2 expression in HepG2.215 cells after 
transfection with miRNA or siRNA for two times 
Two days after transfection of 20nM miRNAs (A) or siRNAs (B) into HepG2.215, we split 
cells and then transfected miRNAs or siRNAs for additional time. After three or four days 
culturing, WE extracted cytoplasmic and nuclear protein to test EZH2 protein by western blot 
analysis (upper panel), extracted HBV RI for southern blot analysis (below panel). We used 
β-actin as loading control. 
4.3 MiR-125b modulates hepatoma cells growth and metabolism 
4.3.1 Tumor suppressor miRNAs do not regulate liver specific factors 
HBV replication is dependent on host cell differentiation status and controlled by a 
variety of cellular transcription factors. Previously, Dr. Xiaoyong Zhang demonstrated 
that miR-1 could up-regulate the liver-specific protein albumin and host nuclear 
receptor NR1H4 so that it enhanced the HBV replication (ZHANG et al. 2011b). 
Therefore, we supposed that these selected miRNAs may also participate in regulating 
these factors expression. We transfected 20nM miRNA mimics into hepatoma cells, 
and three days post transfection, purified RNA for real time RT PCT and cell lysate 
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for western blot. As compared to miR-C or mock, miR-1 could up-regulate both RNA 
and protein level for albumin and NR1H4, while these six new selected miRNAs, 
except for miR-101, could enhance albumin protein slightly, the other five miRNAs 
had no obvious effect on these two protein expressions, especially for miR-125b 
(Figure 4.22). 
 
Figure 4.22 Influence of miRNAs on host cellular factors 
(A) Western blot analysis. 3 days after transfection of 20nM miRNA mimics into HepG2.215 
cells, we collected cell lysate to test albumin and NR1H4 protein expression by western blot, 
using β-actin as loading control. (B) Real time RT PCR analysis. 3 days after transfection of 
20nM miRNA mimics into HepG2.215 cells, we purified total cellular RNA to test albumin 
and NR1H4 RNA and normalized against 106 β-actin transcripts. 
4.3.2 MiR-125b arrests cell cycle at G1 phase and inhibits hepatoma cell 
proliferation 
Next, we tested their effect on cell cycle distribution. We transfected 20 nM miRNA 
mimics into HepG2.215 and Huh7, and then treated cells with cell cycle inhibitors 
aphidicolin (APH), which could block cell cycle at G1 phase or nocodazole (NOC), 
which could block cell cycle at G2/M phase. As for HepG2.215, after treated with 
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APH for 24 hours, more than half percentage of cells stay at G1 phase, but after APH 
was removed for additional 6 hours, most cells could entry into S phase, and there 
were less than 10% cells stay G1 phase for all transfection groups except miR-125b 
group. Compared with miR-C group, there were much more cells in G1 phase in 
miR-99a, 199a-3p and 637, and for miR-125b group, there were about 4 fold cells still 
in G1 phase compared with miR-C group (Figure 4.23A). After treating HepG2.215 
with NOC for 6 hours or 12 hours, even though there were about more than 35% and 
half percentage of cells at G2/M phase, there were still more than 15% of cells at G1 
phase for miR-125b group. Compared with miR-C group, there were more than 2 fold 
and 4 fold cells at G1 phase for miR-125b group. The other groups had no such a 
remarkable effect except of miR-637, which had 2 fold cells at G1 phase compared 
with miR-C after treating cells with NOC for 12 hours (Figure 4.23B). 
 
Figure 4.23 MiRNAs affect HepG2.215 cell cycle progress 
(A) HepG2.215 cells were transfected with 20nM of different miRNA mimics for 24 hours, 
then they were split and treated with cell cycle inhibitor aphidicolin (4μg/ml) for 24 hours or 
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treated for 24 hours and removed for additional 6 hours. (B) After transfection miRNA 
mimics for 24 hours, the cells were split and treated with cell cycle inhibitor nocodazole 
(100nM) for 6 hours or 12 hours. We calculated G1 phase proportion and miR-C group was 
set to 100. 
We also tested their effect on HepG2.215 cell proliferation by H3-thymidine DNA 
synthesis assay. Compared to miR-ctrl, miR-125b could inhibit HepG2.215 cells 
proliferation significantly (Figure 4.24). 
 
Figure 4.24 Influence of miRNAs on HepG2.215 cell proliferation 
After transfection 20nM miRNA mimics for 24 hours, the HepG2.215 cells were split into 
96-well plate for testing their cell proliferation ability by H3 Thymidine labeled DNA 
synthesis assay. 
Besides the HepG2.215 cell line, we also tested their effect on Huh7 cell cycle profile. 
In Huh7 cells, even though G1 phase for all groups was not so consistent as in 
HepG2.215 cells after being treated with APH for 24 hours, there were still about half 
percent cells at G1 phase. Then we compared two groups, the first group was treated 
with APH and removed 6 hours, and the second group was only APH treated for 24 
hours without removed. The results showed that in miR-125b group there was still 1.5 
fold cells at G1 phase compared with miR-C group, whereas, other miRNA groups 
had no obvious difference compared to miR-C (Figure 4.25A). So as to NOC 
treatment, after treated Huh7 cells with NOC for 6 hours or 12 hours, there were also 
much more cells at G1 phase for miR-125b group as compared to miR-C group, other 
miRNAs had no obvious difference compared to miR-C (Figure 4.25B). 
67 
 
 
Figure 4.25 MiRNAs affect Huh7 cell cycle progress 
(A) Huh7 cells were transfected with 20nM of different miRNA mimics for 24 hours, then 
split and treated with cell cycle inhibitor aphidicolin (4μg/ml) for 24 hours or treated for 24 
hours and removed for additional 6 hours. (B) After transfection miRNA mimics for 24 hours, 
the cells were split and treated with cell cycle inhibitor nocodazole (100nM) for 6 hours or 12 
hours. We calculated G1 phase proportion and miR-C group was set to 100. 
The previous results demonstrated that miR-125b could arrest hepatoma cells at G1 
phase, so we want to investigate the molecular mechanisms of miR-125b on cell cycle 
blockage. Retinoblastoma protein (RB) is a key factor that arrests cell cycle progress 
by repressing transcription genes such as E2Fs family which are required for the 
G1-to-S-phase transition. Meanwhile, phosphorylation for RB could inactivate RB 
and allow cell cycle progression from G1 to S phase (GIACINTI and GIORDANO 2006; 
HARBOUR and DEAN 2000; HENLEY and DICK 2012; SINGH et al. 2010). Thus, we 
supposed that miR-125b may regulate RB phosphorylation to disturb cell cycle 
progress. We transfected different concentrations of miR-125b into HepG2.215 and 
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Huh7, 3 days after transfection, we collected cell lysate for phosphorylated RB 
detection by western blot analysis. As compared to miR-C, miR-125b could 
down-regulate RB phosphorylation obviously in dose dependence both in HepG2.215 
and Huh7 cell lines (Figure 4.26). 
 
Figure 4.26 MiR-125b down-regulates RB phosphorylation 
Three days after transfection with 0, 5, 10, 20 or 40nM miR-125b into HepG2.215 (upper 
panel) or Huh7 cells (below panel), we collected total cellular proteins for phosphorylated RB 
detection, The signals were analyzed by using β-actin as loading control and miR-C was set to 
100. 
Normally, cell proliferation and apoptosis are two opposite phenomenon. Our 
previous results showed that miR-125b could inhibit hepatoma cell proliferation, so 
we supposed that miR-125b may promote hepatoma cell apoptosis. The process of 
apoptosis is regulated by a series of signal cascades under certain circumstances. The 
caspase-cascade system plays vital roles in the induction, transduction and 
amplification of intracellular apoptotic signals (FAN et al. 2005). And the activation 
and function of caspases are regulated by various kinds of molecules, such as Bcl-2 
family proteins. So we tested several apoptosis associated protein expressions after 
transfection of different concentrations of miR-125b in HepG2.215, including BCL-2, 
apoptosis marker caspase-3 and cleaved PARP since PARP is one of the main 
cleavage targets of caspase-3. Western blot analysis showed that after transfection of 
miR-125b into HepG2.215 cells, BCL-2 was up-regulated, and cleaved PARP was 
down-regulated in dose dependence, while caspase-3 had no obvious difference 
between miR-C and miR-125b transfected cells (Figure 4.27). The reason why 
miR-125b dose not suppress anti-apoptosis protein BCL-1 expression to up-regulate 
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capsase-3 protein and finally enhance the cleavage ability to PARP is that the 
caspase-cascade system is complicated in vivo, and there are several caspase-cascade 
pathways including, caspase-3, which means that miR-125b dose not simply modulate 
one or several molecules to participate in hepatoma cell apoptosis pathway.  
 
Figure 4.27 MiR-125b modulates apoptosis associated proteins 
Three days after transfection with 0, 5, 10, 20, 40 nM of miR-125b into HepG2.215 cells, we 
collected cell lysates to test BCL-2, caspase-3, cleaved PARP protein expression by western 
blot analysis, and used β-actin as loading control. 
4.3.3 MiR-125b regulates metabolism associated genes in hepatoma cells 
Even though HBV gene expression is regulated mainly at the transcriptional level by 
recruitment of a whole set of cellular transcription factors and coactivators to support 
transcription, there are still many other indirect regulation mechanisms that miRNAs 
may take to participate in HBV life cycle, such as host cellular metabolism and 
cytoskeleton change. We used the RNA sequence assay to figure out pathways and 
genes miR-125b may regulate in hepatoma cells. We transfected 20 nM miR-ctrl or 
miR-125b into HepG2.215 and Huh7 cell lines, and then purified RNA for RNA 
abundance analysis. Our RNA sequence results showed that there were 180 pathways 
in HepG2.215 and 199 pathways in Huh7 which have been regulated by miR-125b, 
and there were about 20000 genes on the RNA level which have been changed by 
miR-125b in hepatoma cells. We sorted out twelve pathways which have more than 
five genes that have been changed after transfection miR-125b into hepatoma cells, 
and there were eight pathways related to cell growth and metabolism, including 
metabolic pathways, carbohydrate digestion and absorption, retinol metabolism, 
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purine metabolism, pancreatic secretion, protein digestion and absorption, bile 
secretion and MAPK signaling pathways. And in these pathways, there were several 
family genes that had both obviously changed in HepG2.215 and Huh7, such as 
Glucuronosyltransferase 2 family, aldo-keto reductase family and ATP-binding 
cassette family. Two pathways were related to the cell skeleton, including regulation 
of actin cytoskeleton and tight junction, such as myosin gene. And two pathways were 
related to immune response, including NF-kappa B signaling pathway and phagosome. 
In these pathways, IL8 and IL1R1 were up-regulated by miR-125b in both Hep2.215 
and Huh7 cell lines significantly (Table 3). 
Table 3 Pathways regulated by miR-125b in hepatoma cells 
 
4.3.4 MiR-125b regulates LIN28B/let-7 axis to modulate HBV replication 
It is reported that LIN28, which is a conserved RNA binding protein and highly 
expressed during embryogenesis and early larval development in the hypodermal, 
neural and muscle cells, is a primal regulator of growth and metabolism in stems cells. 
Loss of LIN28 function could accelerate the differentiation. Furthermore, LIN28 
could inhibit the tumor suppressor miRNA let-7 biogenesis, so that the LIN28/let-7 
pathway plays a specific and tightly regulated role in modulating glucose metabolism 
in mammals (SHYH-CHANG and DALEY 2013; ZHU et al. 2011). Besides, LIN28B is a 
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conserved target gene for miR-125b, so we supposed that miR-125b may regulate 
hepatoma cell metabolism through LIN28B/let-7 axis and finally affect HBV 
replication. 
Our RNA sequence data showed that LIN28B was down-regulated both in HepG2.215 
and Huh7 cells significantly after transfection with miR-125b for three days (Table 4). 
Table 4 Lin28b RNA level in hepatoma cells 
 
And we also confirmed that miR-125b could down-regulate LIN28B protein 
expression in hepatoma cells in dose dependent manner by western blot analysis 
(Figure 28). 
 
Figure 4.28 MiR-125b down-regulates LIN28B protein expression 
Three days after transfection with 0, 5, 10, 20 or 40nM miR-125b into HepG2.215 (upper 
panel) or Huh7 (below panel), we collected total cellular proteins for LIN28B detection 
through western blot analysis by using β-actin as loading control. 
We then selected two siRNAs to knock down LIN28B and detected their influence on 
HBV replication. Our western blot results showed that both siLIN28B 1# and 4# 
could down-regulate LIN28B protein expression efficiently, especially siLIN28B 4# 
(Figure 4.29A and B, upper panels), while only siLIN28B 4# could enhance HBV 
replication and HBsAg expression in HepG2.215 cells after transfection for four days 
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(Figure 29A, middle and below panels). However, in Huh7 cells, there was no 
difference for HBV RI between siR-ctrl and siLIN28B when we cotransfected 
siRNAs and pSM2 for three days (Figure 29B, middle panel). 
 
Figure 4.29 SiLIN28B knocking down efficience and influence on HBV 
Three days after transfection of 20nM siRNAs into HepG2.215 (A) or Huh7 (B), we collected 
total cellular proteins for LIN28B detection, and extracted HBV RI for southern blot and 
supernatant for CMIA assay, and we used β-actin as loading control for western blot analysis. 
As for HepG2.215 cells, after transfection with different concentrations of siLIN28B 
4# for 3 days, the LIN28B protein expression could be down-regulated in a dose 
dependent manner. And we also tested HBV RI, nucleocapsid from intracellular and 
HBsAg and HBeAg from culture media after 4 days of transfection. And the results 
confirmed that in the HepG2.215 cell line, knocking down LIN28B could enhance 
HBV EcDNA, nucleocapsid formation and protein secretion in a dose dependent 
manner (Figure 4.30A). While in Huh7, when we transfected 20nM siLIN28B 4# for 
three days, and then split cells for cotransfection of pSM2 and siLIN28B 4# for 
additional three days, HBV RI could also be accumulated (Figure 30B). 
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Figure 4.30 Knocking down LIN28B enhances HBV replication 
(A) HepG2.215 cells were transfected with 0, 5, 10, 20 and 40nM of siLIN28B 4# for three 
days for the detection of LIN28B expression by western blot (upper panel), and four days for 
HBV RI, nucleocapsid and HBsAg and HBeAg detection by southern blot and CMIA assay 
(middle and below panels). We used β-actin as loading control for western blot analysis. (B) 
Huh7 cells were transfected with 20nM siR-ctrl or siLIN28B 4# for three days, then split cells 
and cotransfected of pSM2 with siRNAs for additional three days for HBV RI, HBsAg and 
HBeAg detection. 
Up to now, nine members have been recognized in the let-7 family, including let-7a, 
let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i, and miR-98. And for some let-7 
family members, there are some sub-family members, such as for let-7a, there are 
let-7a-1, let-7a-2 and let-7a-3. But all let-7 family members are believed to exert 
similar functions since they share a common seed region (Table 5, thick black 
characters), which mediated miRNA interaction with target mRNAs.  
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Table 5 Let-7 family members sequence 
 
Our RNA sequence results showed that there were four let-7 members that could be 
detected with a differential expression after transfected with miR-125b into hepatoma 
cells, including let-7a, 7c, 7d and miR-98 (Table 6). 
Table 6 Let-7 family members changed by miR-125b in hepatoma cells 
 
We also tested the above four let-7 members by miScript real time PCR after 
knocking down LIN28B or the exogenous transfection of miR-125b into hepatoma 
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cells. The results confirmed that in Huh7 cell line, let-7a, 7c, 7d and miR-98 
generation were enhanced significantly after knocking down LIN28B, and in 
HepG2.215 cell line, except let-7c, the other three let-7 members were up-regulated 
by knocking down LIN28B. However, in HepG2.215 cells, the exogenous 
transfection of miR-125b could obviously enhance all four members generation, while 
in Huh7 cells, there was no obvious difference between miR-ctrl and miR-125b 
groups (Figure 4.31). 
 
Figure 4.31 Influence of knocking down LIN28B or exogenous miR-125b on let-7 
generation in hepatoma cell lines 
Three days after transfection with 20nM siR-ctrl, siLIN28B 4# or miR-ctrl, miR-125b into 
HepG2.215 (left panel) or Huh7 (right panel), we purified the total cellular RNA, including 
miRNA using Trizol. The quantification of let-7a, 7c, 7d and miR-98 were carried out with 
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miScript Primer Assay and miScript SYBR Green PCR Kit from QIAGEN. The relative 
miRNA quantification was normalized by U6 snRNA. All reactions were performed in 
triplicate. 
Then we selected and synthesized two let-7 member mimics, let-7a and miR-98 since 
the quantities for these two members were the highest and the lowest ones, and 
transfected them into hepatoma cells for detecting their influence on HBV replication. 
Four days after transfection of 20nM mimics into HepG2.215 or three days after 
cotransfection of 20nM mimics with pSM2 into Huh7, we extracted HBV RI from 
intracellular core particle for southern blot assay. The results showed that exogenous 
miR-98 could enhance HBV replication both in HepG2.215 and Huh7 cell lines 
significantly, while let-7a had no obvious influence (Figure 4.32). The reason for this 
phenomenon may be that the basic abundance for let-7a in hepatoma cells was 
already very high, so that the exogenous mimic could not enhance function. However, 
this did not appear for miR-98, since its abundance in hepatoma cells was really low 
so that exogenous miR-98 mimic could enhance HBV replication obviously (Figure 
4.31). 
 
Figure 4.32 Exogenous let-7 members on HBV replication 
HepG2.215 (upper panel) or Huh7 (below panel) cells were transfected or cotransfected 
pSM2 plasmid with 20nM of miR-C or let-7 members for four or three days, and then we 
extracted HBV RI from intracellular core particle for southern blot assay. 
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5 Disscussion 
Since initial observation, there are about 1733 mature human miRNAs, which have 
been registered in miRBase (WANG et al. 2012d). In liver, miRNAs are abundant, 
such as miR-122 which is described as a liver specific miRNA and has been reported 
in mouse, woodchuck and human livers, in human primary hepatocytes, and in 
cultured liver derived cells (CHANG et al. 2004; CHANG et al. 2003). Besides miR-122, 
many other miRNAs, such as miR-1, miR-16, miR-27b, miR-30d, miR-126, miR-133, 
miR-143, and the let-7 family, are also abundantly expressed in adult liver tissue. 
While miR-122 appears as the most highly expressed miRNA in adult liver, miR-92a 
and miR-483 seem to be more specifically expressed in the fetal liver (GIRARD et al. 
2008). Thus, the liver displays a differential miRNA expression profile during its 
development, so as to hepatocellular carcinoma development. Several studies have 
shown that specific miRNAs are aberrantly expressed in malignant HCC cells or 
tissues compared to non-malignant hepatocytes or tissue (JACOB et al. 2004; KUTAY 
et al. 2006; MENG et al. 2007; VARNHOLT et al. 2008; WONG et al. 2008b). Alteration 
of expression profile in HCC for some miRNAs may be the consequence of malignant 
transformation. Besides, drugs treatment could also change host cellular miRNAs. 
Pedersen for example, demonstrated the IFN-mediated modulation of the expression 
of numerous cellular miRNAs in the treatment of hepatocytes infected with HCV 
(PEDERSEN et al. 2007). For other miRNAs, they may play a role in the transformation 
process.  
MiRNAs, which from the host cells also play a role in building up direct or indirect 
effect in regulating viral genes (BERKHOUT and JEANG 2007; GHOSH et al. 2009; 
LECELLIER et al. 2005). MiRNA-122 has been reported to facilitate the replication of 
HCV, targeting the viral 5’non-coding region (JOPLING et al. 2005). Besides host 
cellular miRNAs, genes encoding miRNAs have also been found in viruses, and viral 
miRNAs have a regulatory effect on their protein-coding genes (BERKHOUT and 
JEANG 2007). This regulatory effect may be beneficiary to the virus towards 
maintaining its replication, latency and evading the host immune system. As to HBV, 
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so far none of the HBV-encoded miRNAs have been identified. But cellular miRNAs 
have shown to be able to regulate HBV at the transcription level either by targeting to 
cellular transcriptions factors which are required for HBV gene expression, or by 
directly bind to HBV transcripts (LIU et al. 2011). And in our previous results, Dr. 
Xiaoyong Zhang found that miR-1 could increase HBV transcription under the 
control of the HBV core promoter in a farnesoid X receptor alpha dependent manner 
(ZHANG et al. 2011b). Other than miRNAs affecting viral translation, there are reports 
on HBV replication, such as miR-122, which is found to suppress HBV replication 
indirectly through HO-1 (QIU et al. 2010). 
5.1 Cancer related miRNAs down-regulated in hepatoma cells could enhance 
HBV replication 
The major risk factor for HCC is chronic HBV and/or HCV infection. HBV, HCV, 
and their functional proteins are likely to exhibit their pathogenic roles via regulating 
the expression of host-derived miRNAs in the affected liver. The deregulated 
miRNAs serve as mediators of virus–host interaction, playing an important role in 
persistent infection, carcinogenesis, and HCC treatment via regulating host gene 
expression. Host miRNAs cannot only be regulated by virus infection but also affect 
virus replication and viral protein expression via specifically binding to the viral 
sequences or targeting some related host genes, thus, playing an important role in the 
virus-induced hepatocarcinogenesis (ZHANG et al. 2012a). For example, Guo et al. 
demonstrated that miR-373 is up-regulated in HBV-infected livers. Furthermore, the 
enhanced expression of miRs-372/373 in HepG2 cells transfected with 1.3-fold HBV 
genome stimulates the production of HBV proteins and HBV core-associated DNA 
via targeting nuclear factor I/B (GUO et al. 2011b). Ladeiro et al. reported the 
overexpression of miR-96 in HBV-associated hepatocellular carcinoma (HCC) 
(LADEIRO et al. 2008), and Ura et al. proposed that differential miRNA expression 
contributed to the different progression between HCV and HBV infection to HCC 
(URA et al. 2009). Liu et al. observed that miR-181a was up-regulated in 
HBV-producing HepG2.2.15 cells, and that one of its putative targets, human 
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leukocyte antigen A (HLA-A), was repressed, possibly related to decreased viral 
resistance (LIU et al. 2009). All these reports suggest that there is a relationship 
between miRNAs and HBV in HCC. In our results, we tested the abundance of 
several cancer related miRNAs, including miR-99a, miR-101 and miR-125b, and 
found their quantities were remarkably reduced in hepatoma cells compared with in 
PHH. MiR-99a and miR-125b in HepG2.215, which comes from HepG2 cell line and 
contains HBV dimer, were much lower than in HepG2 (Figure 4.16). Moreover, after 
exogenously transfection miR-99a and miR-125b into HepG2.215 cell line, HBV 
replication was obviously up-regulated, and exogenous miR-101 could also enhance 
HBV replication in Huh7 cell line but not in HepG2.215 and HepG2. The reason for 
this phenomenon may be that the abundance for mature miR-101 in Huh7 cells was 
much lower than in the other two hepatoma cell lines. As for miR-125b, besides its 
enhancement of HBV replication in HepG2.215 cells, it also enhanced HBV 
replication in HepG2 and Huh7 cell lines (Figure 4.1 and 4.2). This phenomenon is 
consistent with Winther et al. who reported that the quantity for miR-125b in HBeAg 
positive CHB patients is higher than in HBeAg negative patients (WINTHER et al. 
2013). 
On the other hand, some miRNAs down-regulated in HCC are beneficial for HBV 
survival, such as miR-122. MiR-122 levels are significantly decreased in 
HBV-infected patients compared with healthy controls, which may facilitate viral 
replication and persistence (CHEN et al. 2011c; WANG et al. 2012c).  
5.2 MiRNAs which could arrest hepatoma cell at G1 phase are beneficial for 
HBV replication 
Viruses may transform host cell growth status to benefit its survival. Huang et al. 
demonstrated that HBV replication was active in quiescent hepatocytes but slowed 
when hepatocytes started to divide (HUANG et al. 2004). Wang et al. found that HBV 
x protein could inhibit the capability of proliferation of HepG2.2.15 cells by 
regulating cell cycle gene expression and inducing G1 arrest (WANG et al. 2011b). 
Gearhart et al. demonstrated that cell cycle progression affected HBV replication in 
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cultured primary rat hepatocytes, and that HBV replication requires primary rat 
hepatocytes in G1 phase (GEARHART and BOUCHARD 2010). All these studies reflect 
that HBV replication is affected by the hepatocytes’ growth ability, and the G1 phase 
is more beneficial for HBV replication. In our results, we found one miR-125b could 
block cell cycle at G1 / S phase transition and inhibit hepatoma cells proliferation, and 
these results are consistent with several groups that miR-125b could interfere with 
hepatoma cell growth (BI et al. 2012; JIA et al. 2012; KIM et al. 2013; LIANG et al. 
2010). Meanwhile, our results demonstrated that miR-125b could up-regulate HBV 
replication in different hepatoma cell lines (Figure 4.1, 4.2, 4.23, 4.24 and 4.25).  
5.3 MiRNAs involved in multiple steps in HBV life cycle directly or indirectly 
Host cellular miRNAs could affect both transcription and replication in HBV life 
cycle directly or indirectly. Although HBV is a DNA virus, its transcripts might be 
targeted and regulated by cellular miRNAs. Some cellular miRNAs were found to be 
capable of inhibiting or stimulating viral replication by directly targeting to viral 
RNAs (CULLEN 2009; LIN and FLEMINGTON 2011). For example, bioinformatics 
analysis of six miRNAs with ViTa database suggested a putative binding site for 
miR-199a-3p in the HBsAg coding region, and the other binding site for miR-210 in 
the HBV pre-S1 region. The direct effect of these two miRNAs on HBV RNA 
transcripts was also validated by GFP reporter assay. This study suggests 
up-regulation of miR-199a-3p and miR-210 in HepG2 2.2.15 cells resulting in a 
reduction of HBV replication by a direct binding to the viral RNAs (ZHANG et al. 
2010a). In addition, Russo's group found miR-125a-5p is able to interact with HBV 
surface antigen and interfere with its expression, thus reducing the amount of secreted 
HBsAg (POTENZA et al. 2011). 
HBV is controlled within the host hepatocyte by a number of cellular proteins at 
multiple steps of the HBV replication cycle in a complex way. Control of HBV at the 
step of transcription influences both HBV gene expression and replication. There are 
several studies on host cellular transcription factors modulated potentially by cellular 
miRNAs in host hepatocytes, and so affecting HBV transcription. CAAT 
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enhancer-binding protein (C/EBP) α and β, for example, are co-expressed in 
hepatocytes and are involved in the hepatocyte metabolism and proliferation. C/EBP 
can bind and activate the HBV Enhancer II in a dose-dependent manner 
(LOPEZ-CABRERA et al. 1991), and also binding to core promoter and S promoter to 
activate their transcription (BOCK et al. 1999; LOPEZ-CABRERA et al. 1990). Wang et 
al. showed that C/EBP-β was targeted and negatively regulated by miR-155 (WANG et 
al. 2009), which could down-regulate HBV transcription. A second example is 
miR-372. An inhibition of miR-372 results in reducing the expression of its target 
gene, PRKACB, which induces phosphorylation of CAMP- response element binding 
protein (CREB) and dissociated CREB from the promoter (WANG et al. 2010a). 
CREB was known to be required for the expression of all HBV transcription units for 
binding to viral enhancer I (KIM et al. 2008). And in our previous results, Dr. 
Xiaoyong Zhang found that miR-1 was able to enhance the HBV core promoter 
transcription activity by augmenting FXRA expression, a positive transcription factor 
(ZHANG et al. 2011b).  
Other than miRNAs affecting viral translation, there are reports on HBV replication. 
In Qiu's study, silencing miR-122 in HBV transfected Huh-7 cells with antisense 
miR-122 significantly increases HBsAg and HBeAg secretion (QIU et al. 2010). 
Furthermore, miR-152 may be a factor in regulating the methylation of host and viral 
cccDNA by modulating DNMT1 expression (ZHANG et al. 2009). Collectively, host 
miRNAs can modulate HBV transcription and replication by regulating cellular 
factors that do not direct bind to viral genome. 
In our results, we found that miR-125b dose not bind to the HBV genome directly 
even though it was predicted that the seed sequence of miR-125b could target HBV 
polymerase and s gene region by computational analysis (Figure 4.5). Besides, 
miR-125b neither regulated the HBV four promoters activity nor regulated the HBV 
RNA transcription process (Figure 4.10-12). But miR-125b could up-regulate HBV 
core protein expression, core particle formation, HBV RI accumulation as well as 
progeny section in a dose dependent manner in several hepatoma cell lines (Figure 4.6, 
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4.7 and 4.13). Moreover, miR-125b could enhance HBV replication with miR-1 in a 
synergistic manner (Figure 4.14). All these results demonstrated that, in contrast to 
miR-1, miR-125b participated in HBV life cycle in the post transcriptional process. 
Since phosphorylation of HBV core protein is important in post transcriptional steps 
in HBV life cycle, including viral RNA packaging, DNA synthesis, and subcellular 
localization (CHEN et al. 2011a; LUDGATE et al. 2011; LUDGATE et al. 2012; WANG et 
al. 2012a; WITTKOP et al. 2010), we supposed that miR-125b may strengthen HBcAg 
protein stability and nucleocapsid assembly ability through modulation core protein 
phosphorylation and dephosphorylation process, but this hypothesis should be further 
confirmed.  
5.4 MiR-125b is involved in regulating multiple pathways in hepatoma cells 
which may affect HBV replication 
One miRNA could regulate several target genes, this implies that in different tissues 
one miRNA may have different regulatory targets or pathways for one phenomenon, 
and on the other hand, one miRNA could target multiple signalling pathways for one 
phenomenon in one tissue (SURDZIEL et al. 2011). As to liver tissue, even though 
hepatoma cell lines used in different groups were all extracted from liver tumor tissue, 
there were still different physiological statuses, such as different differentiation degree, 
molecular components or activated pathways, which may all influence one miRNA 
modulation mechanism. Huang et al. for example, demonstrated that miR-125b could 
arrest bladder cancer cells at G1 phase through directly suppressing target protein 
E2F3 expression, which was a critical factor for G1/S transition and was over 
expressed in most of poorly differentiated bladder cancers (HUANG et al. 2011). Wu et 
al. reported that miR-125b regulated the proliferation of glioblastoma stem cells by 
targeting E2F2 (WU et al. 2012). However, in our results, we found that miR-125b did 
not down-regulate E2F3 protein expression in hepatoma cells, so as to other E2Fs 
family members (data not showed), but decreased RB phosphorylation which is a key 
factor that arrests cells during the G1 phase of the cell cycle by repressing 
transcription genes such as E2Fs family (Figure 4.26).  
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At the beginning, our results confirmed that the quantity for mature miR-125b in 
hepatoma cells was significantly decreased compared with PHH, so we want to find 
out the reasons. MiR-125b gene promoter is enriched in CpG dinucleotides, which is 
benefit for DNA methylation, so miR-125b transcription is modulated by DNA 
methylase (ALPINI et al. 2011; HE et al. 2012a; ZHANG et al. 2011c). Enhancer of 
zeste homolog 2 (EZH2) acts as a methyltransferase which is thought to be involved 
in targeting transcriptional regulators, and it is reported that EZH2 could 
epigenetically silence multiple tumor suppressor microRNAs in liver (AU et al. 2012; 
ONDER et al. 2012). Thus, we supposed that EZH2 may participate in modulating of 
mature miR-125b generation in HCC. However, our results showed that knocking 
down EZH2 in hepatoma cells had no influence on mature miR-125b generation 
(Figure 4.18). Unexpectedly, we found that exogenous miR-125b could suppress 
EZH2 protein expression both in HepG2.215 and Huh7 cell lines. After further study, 
we found that knocking down EZH2 in Huh7 could enhance HBV replication but not 
in HepG2.215 cell line (Figure 4.19, 4.21). This phenomenon showed that in different 
hepatoma cell lines, miR-125b have different regulatory mechanisms on HBV 
replication. 
Moreover, Liang et al. elaborated that miR-125b suppressed human liver cancer cell 
proliferation and metastasis by directly targeting oncogene LIN28B while Alpini et al. 
showed that miR-125b inhibited hepatoma cells proliferation by targeting placenta 
growth factor but did not regulate LIN28B in HCC (ALPINI et al. 2011; LIANG et al. 
2010). It is yet unclear which genes or pathways that miR-125b may take in 
regulating hepatoma cells growth and metabolism. And we want to sort out which 
genes or pathways miR-125b may take in hepatoma cells in modulating HBV 
replication. As HBV replication is related to host cell metabolism, for example, in 
2006, Shlomai et al. reported that HBV was tightly regulated by changes in the body's 
nutritional state through the metabolic regulator PGC-1alpha (SHLOMAI et al. 2006). 
And recently, Shyh-Chang et al. reported that LIN28 is a primal regulator of growth 
and metabolism in stem cells, and that a loss of its function accelerates differentiation 
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(SHYH-CHANG and DALEY 2013). Moreover, LIN28 could inhibit let-7 biogenesis 
which could control glucose homeostasis and insulin sensitivity. LIN28/let-7 pathway 
plays a specific and tightly regulated role in modulating glucose metabolism in 
mammals (FROST and OLSON 2011; ZHU et al. 2011). And our results were consistent 
with these of Liang’s group that miR-125b could down-regulate LIN28B protein 
expression in hepatoma cells (Figure 4.28), and that knocking down LIN28B could 
up-regulate let-7 family members generation and also enhance HBV replication 
(Figure 4.30 and 4.31). 
The molecular mechanisms for miR-125b on regulating HBV replication are 
complicated, there is still a lots of work needs to be done in the future to figure out 
more pathways and make clear what is the difference between the various hepatoma 
cell lines for miR-125b modulation.  
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6 Summary 
In our present study, we tested the influence of six liver cancer related miRNAs on 
HBV replication and hepatoma cell growth, and found that miR-125b could 
up-regulate HBV replication and suppress hepatoma cell growth. Moreover, we found, 
different from previous investigated miR-1, that miR-125b neither regulates hepatoma 
cells differentiation nor participates in HBV transcription level. More detailed 
functions for miR-125b that we found in this study are summarized as follows: 
①  MiR-125b could specifically up-regulate HBV replication both in HBV stable 
expression or transient transfection system, while it has no influence on HCV 
replication. 
② Mature miR-125b is down-regulated in HCC compared with PHH, while the 
reduction is neither attributed to methylase EZH2 nor to HBx. On the contrary, 
exogenous miR-125b could decrease EZH2 both in HepG2.215 and Huh7, but 
only the decrease in Huh7 causes the enhancement of HBV replication. 
③ The action for miR-125b on HBV replication is seed sequence specific, 
anti-miR-125b inhibitor could suppress mature miR-125b generation and also 
HBV replication in hepatoma cells. 
④ MiR-125b neither binds to HBV genome directly nor regulates the HBV 
transcription process, but it enhances HBV core particle formation and progeny 
secretion in a dose dependent manner. 
⑤ Exogenous miR-125b could inhibit hepatoma cells proliferation and block cell at 
G1/S phase transition through a decrease of RB phosphorylation, but it does not 
regulate liver specific protein ALB or cellular transcription factor FXRA 
expression.  
⑥ Exogenous miR-125b could regulate primal metabolism associated genes 
transcription in hepatoma cells, such as LIN28B, which is a target gene for 
miR-125b, and this may be benefit for the HBV replication. 
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7 Zusammenfassung 
In der vorliegenden Arbeit wurde der Einfluss von sechs mit Lebertumoren in 
Beziehung stehenden miRNAs auf die Replikation von HBV und das Wachstum von 
Leberkrebszellen untersucht. Dabei zeigte sich, dass miR-125b die HBV-Replikation 
hochregulieren und das Wachstum von Leberkrebszellen unterdrücken konnte. 
Darüber hinaus hat sich gezeigt, dass, anders als im Falle der bereits untersuchten 
miR-1, miR-125b weder die Differenzierung von Leberkrebszellen reguliert noch an 
der Transkription von HVB beteiligt ist. Weitere Funktionen von miR-125b, die im 
Rahmen dieser Arbeit aufgedeckt wurden, werden im Folgenden im Detail 
zusammengefasst: 
1. MiR-125b konnte besonders die HBV-Replikation sowohl im stabilen 
Expressions- als auch im transienten Transfektionssystem hochregulieren, 
wohingegen es keinerlei Einfluss auf die HCV-Replikation hatte. 
2. Reife miR-125b wird, im Vergleich zu PHH, in HCC herunter reguliert, wobei 
die Reduktion weder mit Methylase EZH2 noch mit HBx in Zusammenhang 
steht. Im Gegenteil, exogene miR-125b konnte EZH2 sowohl in HepG2.215 
als auch in Huh7-Zellen herabsetzen, wobei nur die Reduktion in Huh7 die 
HBV-Replikation erhöhen konnte. 
3. Das Verhalten von miR-125b bei der HBV-Replikation ist abhängig von „seed 
sequence“; der anti- miR-125b-Inhibitor konnte sowohl die Generierung von 
reifen miR-125b als auch die HBV-Replikation in Leberkrebszellen 
unterdrücken. 
4. MiR-125b bindet weder direkt an das HBV-Genom noch reguliert es den 
HBV-Transkriptionsprozess; allerdings erhöhte es dosisabhängig die Bildung 
und Sekretion von HBV Core Partikeln. 
5. Exogene miR-125b konnte die Proliferation von Leberkrebszellen inhibieren 
und durch eine Verringerung von RB Phosphorylierung die Zellen in der 
G1/S-Phase blockieren, jedoch war es nicht in der Lage, das Leber-spezifische 
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Protein ALB oder die Expression des zellulären Transkriptionsfaktors FXRA 
zu regulieren. 
6. Exogenes miR-125b konnte die Transkription von Primärmetabolismus 
assoziierten Genen in Leberkrebszellen regulieren, wie z.B. LIN28B, welches 
ein Zielgen für miR-125b darstellt, was für HBV-Replikation förderlich sein 
kann. 
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9 Abbreviations 
3'-UTR 3'-untranslated region 
5'-UTR 5'-untranslated region 
APH aphidicolin 
C/EBP CCAAT/enhancer-binding protein 
cccDNA circular covalently closed DNA 
CDK2 cyclin-dependent kinase 2 
CHB chronic hepatitis B  
CREB cyclic-AMP response element binding protein 
CTD C-terminal domain 
DIO diet-induced obese mice 
DMEM Dulbecco’s Modified Eagles’s Medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DNMT3A DNA methyltransferase 3A 
E.coli Escherichia coli 
EDTA ethylenediaminetetraaceticacid 
ER endoplasmic reticulum 
EZH2 enhancer of zeste homolog 2 
FBS fetal bovine serum 
FNDC3B fibronectin type Ⅲ domain containing 3B 
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FOXO1 forkhead box protein o 1 
FXR farnesoid X receptor 
g gram 
HBcAg hepatitis B core antigen 
HBsAg hepatitis B surface antigen 
HBV hepatitis B virus 
HBV RI hepatitis B virus replicative intermediate 
HBx hepatitis B x antigen 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
HNF hepatocyte nuclear factor 
HSP27 heat shock protein 27 
IFN interferon 
IGF1R insulin-like growth factor 1 receptor 
IU international unit 
kb kilo base pair 
l liter 
LXRs liver X receptors 
m milli 
MAPK mitogen-activated protein kinase 
MCMV murine cytomegalovirus 
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MEM minimum Essential Medium 
min minute 
miRNAs microRNAs 
mTOR  mammalian target of rapamycin 
NOC nocodazole 
ob/ob leptin-deficient mice 
PBS phosphate buffered saline 
pCP  plasmid contains HBV core promoter region 
PCR polymerase chain reaction 
PCR polymerase chain reaction 
pgRNA pregenomic RNA 
pHBV1 plasmid contains HBV fragment 1 
pHBV2 plasmid contains HBV fragment 2 
pHBV3 plasmid contains HBV fragment 3 
pHBV3'UTR plasmid contains HBV 3'-termnal region 
pHBVFL  plasmid contains HBV full length genome 
PHH primary human hepatocyte 
pRB  phosphorylated retinoblastoma protein 
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